Examining the Quality of Life in Primary Headaches by Manhalter, Nóra
1 
 
Examining the Quality of Life in Primary Headaches 
 
 
PhD Thesis 
 
Nora Manhalter, MD 
 
 
Semmelweis University 
János Szentágothai  Doctoral School of Neurosciences 
 
 
 
 
 
 
 
 
                          
 
 
 
Supervisor:  Csaba Ertsey, MD, PhD 
 
Official reviewers:  Délia Szok, MD, PhD 
         György Purebl, MD, PhD 
 
Head of the Final Examination Committee:  Professor Ferenc Túry, MD, DSc 
 
 
Members of the Final Examination Committee:  Ildikó Vastagh, MD, PhD 
Attila Valikovics, MD, PhD 
 
 
Budapest 
2015 
DOI:10.14753/SE.2016.1860
2 
 
 
Table of contents 
 
1. List of abbreviations                      5 
2. Background and literature                     7 
2.1 Introduction                         7 
2.1.1 Health related quality of life                    8 
2.1.2 Objective and subjective indicators in headache disorders    8 
2.1.3 Health related quality of life in headache disorders             9 
2.2 HRQoL questionnaire types                         9 
2.3 HRQoL questionnaire construction                       11 
2.4 Validation of a HRQoL questionnaire                     11 
2.5 Reliability                              12 
2.6 Validity                               13 
2.7 Validating an instrument in different languages              14 
2.8 Burden of headache and measuring HRQoL in headache             15 
2.8.1 Introduction                           15 
2.8.2 HRQoL instruments used in headache                  16 
      2.8.2.1 Generic Instruments                     17 
2.8.2.2 Headache specific instruments           19 
3. Aims                                   24 
4. Methods                                 25 
4.1 Common elements of the studies                       25 
4.1.2 Patients                             25 
4.1.2 Data recording                          26 
4.1.3 Methods                            26 
4.2. Examination of health-related and condition-specific quality of life  
in episodic cluster headache                    27 
4.2.1 Background and objective                27 
4.2.2 Methods                                 27 
 
 
 
DOI:10.14753/SE.2016.1860
3 
 
 
 
4.3. Development of the Comprehensive Headache-specific Quality  
of life Questionnaire                      28 
4.3.1 Introduction                           28 
4.3.2 Development process of the new headache-specific questionnaire 29 
4.3.2.1 Relevant item identification                 30 
4.3.2.2 Development of a draft version              30 
4.3.2.3 Psychometric testing of a draft version, and the  
development of the final version                     31 
4.3.2.4 Description of the Comprehensive Headache-related  
QOL Questionnaire                 32 
4.4.Validation of the Comprehensive Headache-specific Quality  
of life  Questionnaire                        33 
4.4.1 Validation in migraineurs and tension type headache patients    33 
4.4.1.1 Objective                           33 
4.4.1.2 Methods                           33 
4.4.2 Validation in medication overuse headache                 35 
4.4.2.1 Introduction                                   35 
4.4.2.2 Objective                                 35 
4.4.2.3 Methods                             35 
4.4.3 Examination of responsivity in medication overuse headache   37 
4.4.3.1 Introduction                     37 
4.4.3.2 Objective                          38 
4.4.3.3 Methods                           39 
5. Results                              43 
5.1. Examination of health-related and condition-specific quality of life  
in episodic cluster headache                                            43 
5.2 Validation of the Comprehensive Headache-specific Quality of life  
Questionnaire                              49 
5.2.1 Validation in migraineurs and tension type headache patients    49 
5.2.2 Validation in medication overuse headache                           61 
5.2.3 Examination of responsivity in medication overuse headache   64 
 
DOI:10.14753/SE.2016.1860
4 
 
 
6. Discussion                                 70 
6.1 Examination of health-related and condition-specific quality of life  
in episodic cluster headache                          70 
6.2 Validation of the Comprehensive Headache-specific Quality of life  
Questionnaire                              74 
6.2.1 Validation in migraineurs and tension type headache patients    74 
6.2.2 Validation in medication overuse headache                     81 
6.2.3 Examination of responsivity in medication overuse headache   82 
7. Conclusion                                                            84 
8. Summary /Összefoglalás                       89 
9. References                              91 
10. Publications                            101 
11. Acknowledgments                              102 
12. Appendix                             103 
12.1 Comprehensive Headache-related QOL Questionnaire             103 
12.2 Fejfájással Kapcsolatos Átfogó Életminőség-Kérdőív                      108 
  
DOI:10.14753/SE.2016.1860
5 
 
1. List of abbreviations 
 
24-hour MQoLQ  24-hour Migraine Quality of Life Questionnaire 
BP    bodily pain 
CDH   chronic daily headache  
CH    cluster headache 
CHQQ   Comprehensive Headache-related QOL Questionnaire  
CM    chronic migraine 
CTTH    chronic tension type headache 
EF    emotional function 
EM    episodic migraine 
GH    general health 
HDI    Headache Disability Inventory  
HIT-6    Headache Impact Test  
HRQoL  health-related quality of life  
IHS    International Headache Society  
M   migraine 
MH    mental health 
MIDAS  Migraine Disability Assessment Score  
MOH    medication overuse headache  
MOS    Medical Outcomes Study 
MSQ2.1   Migraine-specific Quality of Life Questionnaire 
MSQOL   Migraine-Specific Quality of Life measure  
PF  physical functioning  
PROs    patient reported outcomes  
QOL   quality of life  
QVM    Qualite´de Vie et Migraine 
RE    role emotional functioning  
RP    role physical functioning 
RP    role-preventive 
RR    role-restrictive 
SF    social functioning  
SF-20    20-Item Short Form Health Survey  
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SF-36    36-Item Short Form Health Survey  
TTH    tension type headache 
VAS    visual analogue scale 
VT    vitality 
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2. Background and literature  
 
2.1 Introduction 
 
In medical practice several outcome measures are used to describe the patients' 
condition.  Some of these are objective, i.e. they can be observed by the investigator (eg.  
tremor, gait), and/or they can be reproducibly measured by appropriate methods (eg. 
blood pressure, lab results). Other health relevant indicators are subjective and 
described using the patient’s own assessment (eg. pain, mood, sleep quantity or sleep 
quality). In recent decades the measurement of these patient reported outcomes has 
become very frequent. 
 
Patient reported outcomes (PROs) include all information, which is communicated 
directly by the patient and describes his/her health and emotional status, or medical 
conditions, and the consequences thereof. As follows, the information gathered by 
PROs is not influenced by the interpretation of health care providers. These pieces of 
information thus create a unique picture of the patient's perspective about his/her illness 
and the impact of medical treatment. Table 1 summarizes the most important aspects 
and examples of objective and subjective indicators. 
 
Table 1. Indicators in medical practice VAS: visual analogue scale 
 
OBJECTIVE SUBJECTIVE 
observable by the investigator communicated by the patient 
measurement methods: physical, chemical, 
histological, etc. 
measurement methods: questionnaire, 
interview, VAS, etc. 
measurable measurable (with limitations) 
reproducible reproducible (with limitations) 
Examples 
 Blood pressure 
 Body temperature 
 Laboratory results 
 DNA tests  
 Histology resuls 
Examples 
 Burden of illness 
  Pain 
  Sleep quantity 
  Mood  
  Quality of life 
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2.1.1. Health related quality of life 
 
Quality of life is „a broad-ranging concept affected in a complex way by the persons’ 
physical health, psychological state, level of independence, social relationship and their 
relationship to salient features of their environment” (1).  
 
Health-related quality of life (HRQoL) is a more circumscript entity. Health is a state of 
complete physical, mental and social well-being and not merely the absence of disease 
or infirmity (WHO definition of Health) (1). Health-related quality of life  represents the 
overall effect of illness and its therapy, as reported and evaluated by the patient (2). In 
this respect, HRQoL is to be distinguished from functional status, which provides an 
objective assessment of a patient’s physical and emotional capabilities by medical 
personnel (3). HRQoL questionnaires are among the most commonly used PRO 
measurement tools.  
 
Beside the ’hard’ indicators – i.e. mortality, morbidity – which are  traditionally applied 
for measuring the efficiency of health care activities, PROs describing the patients’ 
subjective experiences – including life quality measurements – are gaining more and 
more attention. Practical experiences confirm – mainly in case of chronic diseases– that 
better  values, shown by objective indicators used in medical work, are not necessarily 
accompanied by patients’ sense of feeling better (4, 5). On the other hand, in case of 
several medical conditions, the quality of life is an independent predictor of disease 
progression and/or outcome. In end-stage renal disease perceived mental health was 
found to be an independent predictor of mortality and morbidity (7). Quality of life is a 
predictor of survival in pancreatic cancer and HIV-infected adults, too (8, 9). 
Information about quality of life is therefore very important for decision making in very 
different, and also severe diseases (8). 
 
2.1.2. Objective and subjective indicators in headache disorders 
 
In the field of headache research, ‘objective’ indicators (ie. indicators which are not 
dependent on any input from the patients) are not available. As headache is a subjective 
experience, the most commonly used indicators, such as number of days with headache, 
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headache severity, or analgesic consumption, are all reported by the patients. To try to 
overcome this issue, a number of standardized endpoints have been developed, such as 
the Visual Analogue Scale (VAS) and – more importantly – the International Headache 
Society’s 4-point headache severity scale. A number of headache diaries, both paper-
and-pencil and electronic ones, have also been conceived and are used both in clinical 
trials and everyday medical practice. Lately, these indicators have increasingly been 
supplemented by other subjective indicators, such as quality of life, disability, or 
headache impact.  
 
2.1.3. Health related quality of life in headache disorders 
 
HRQoL assessment tools can either assess the patients’ quality of life as a whole or 
assess the effect of a given condition. Accordingly, a distinction between overall 
HRQoL and disease-specific HRQoL is necessary. Overall HRQoL is a concept that 
includes physical and mental functioning and well-being, social and role disability, and 
general health perceptions of the individual (10). On the other hand, disease-specific 
HRQoL describes the particular impact of a selected condition on HRQoL. 
 
 
2.2 HRQoL questionnaire types  
 
Although HRQoL can most precisely be assessed by a detailed patient interview, this 
approach is not practical because of a number of reasons, including issues regarding the 
reproducibility and comparatibility of data, feasibility and examiner burden. To 
overcome these difficulties while aiming at assessing the patients’ quality of life in 
detail, a number of HRQoL questionnaires (also commonly called HRQoL instruments) 
were developed.  There are two basic types of HRQoL questionnaires: generic or 
disease-specific questionnaires.  
 
Generic HRQoL questionnaires measure overall HRQoL. They include questions that 
represent those aspects of health that are important for the majority of people. Thus, 
these instruments permit the comparison of the impact of one illness with that of others 
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and also with values of those who are well. They can measure the effect of various 
healthcare interventions and therefore can be useful, among others, in analysing cost-
efficiency or planning resource allocation in health economics studies. Generic 
instruments may, however, be unresponsive to changes in specific conditions (10). 
There are numerous generic quality of life (QOL) instruments in use, the most widely 
used being the Short Form Health Survey (11).  
 
Disease-specific HRQoL questionnaires focus on problems associated with single 
disease states, allow comparisons of illnesses which share the leading symptoms, and 
can be helpful in selecting the most appropriate therapy for the patient and monitoring 
its efficiency. Moreover, they may better reflect the particular impact of a selected 
condition (10). On the other hand, these questionnaires are not suitable to compare the 
impacts of different conditions with different symptomatologies.   
 
Measuring health related quality of life has become a widely accepted and popular 
method for assessing health status, it is a relevant and quantifiable outcome of care, 
therapy quality and effectiveness (12, 13). The standardized evaluation of HRQoL 
makes it possible to quantify the burden of illness. Although measuring health related 
quality of life can be useful in individual persons, it is particularly useful in assessing 
the impact of disease in groups of patients and it is often used as end point tool in 
clinical studies. Further, it is also helpful in pharmacoeconomic evaluations and 
appropriate allocation of health care resources. The subjective evaluation of the impact 
of a disease on the individual's quality of life has become possible with the development 
of HRQoL instruments and the demonstration of their statistical and psychometrical 
properties. HRQoL scales are used to complement available measurements by 
incorporating the patient's point of view. The primary advantages of using such scales in 
addition to clinical rating scales is the reflection of the patients own assessments of their 
health, which often differs considerably from clinicians or even carers views (4). 
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2.3 HRQoL questionnaire construction   
 
QOL instruments usually study more domains of QOL. A domain refers to a specific 
area of behaviour or experience, such as work performance, social functioning, sleep, 
leisure activities, etc. The domains usually cover the three main dimensions of health-
related QOL: physical, mental and social (10), which have their roots in the World 
Health Organization’s definition of health (1).  
 
The first important step in the development of a QOL instrument is the identification of 
relevant items. This is usually based on interviews with the members of the target 
population (i.e. patients suffering from a given condition). The items have to be 
meaningful both for the patients and for their treating clinicians. The next step is testing 
the draft version on a group of patients. An important aspect is that the questions have 
to be easily understood, so a detailed input from this patient group is required about the 
items and instructions of the questionnaire. After making the adjustments that were 
suggested, the corrected version of the instrument should be tested on a larger group in 
order to have data to apply quality criteria to item selection. Redundant or insignificant 
items must be removed after testing the corrected version, and the resulting final version 
is then to undergo the validation process.  
 
 
2.4 Validation of a HRQoL questionnaire  
 
Like in the case of other scales, the properties of HRQoL scales should be established in 
the population studied before the scale can be used for further investigations (4). The 
validation of a questionnaire requires testing its psychometric properties, most 
importantly its reliability and validity. Besides the adequate psychometric properties, 
the length and ease of use of a questionnaire are important aspects of its usability (14) 
and questionnaire length can have a threshold effect on response rate (15). 
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2.5 Reliability 
 
Reliability is the degree to which a test consistently measures what it aims to measure. 
The methods of assessing reliability include the test–retest method, the use of two 
alternative questionnaires, and measuring the internal consistency. 
 
Test–retest method (test–retest analysis) means the repeated application of the same 
questionnaire. Test–retest analysis usually requires a 4-week period between the two 
test sessions in order to avoid recall bias. During this period every circumstance that 
could possibly influence the patients’ responses, including the therapy, should be 
unchanged. The correlation coefficient obtained during the analysis is called stability 
coefficient, which is considered adequate if it exceeds 0.8 (16). Although determining 
the stability coefficient seems to be straightforward, a number of problems arise in 
connection with this method. Basically, the two applications of the questionnaire are not 
fully independent, as the patients may remember their answers given at the first time. 
On the other hand, if the time interval between the two tests is too long, the measured 
parameter can no longer be considered as unchanged (17) . 
 
The use of two alternative questionnaires measures the equivalence of two 
questionnaires, this requires prior statistical evaluation one of the questionnaires. The 
alternative questionnaires have to be developed independently. To assess the 
equivalence of the questionnaires a further analysis is required, which may be a 
limitation for using this method (18).  
 
Measuring the internal consistency requires calculating either the split-half reliability, 
or Cronbach’s alpha. The so-called "split-half" method analyses the correlation of the 
scores of half-questionnaires, after an accidental division of the instrument’s items in 
two parts. A limitation of this method is, that a questionnaire can be divided in two parts 
in several ways, resulting in different internal consistency values for the same 
instrument. Another method is calculating the inter-item correlation, determined by the 
Cronbach’s alpha coefficient. In this case, the correlation between each item and the 
whole instrument is calculated:  Cronbach’s alpha coefficient shows the average of the 
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correlation values (17). Internal consistency is generally considered adequate if 
Cronbach’s alpha exceeds 0.7, and considered excellent with values in excess of 0.9. If 
an instrument is to be used in the clinical setting, rather than for the comparison of 
groups only, an alpha exceeding 0.9 is the minimum requirement  (19).  
 
 
2.6 Validity 
 
Validity refers to the degree to which an instrument can accurately assess the specific 
concept that the research is attempting to measure (10). A high-quality QOL instrument 
is required to demonstrate different forms of validity, such as criterion validity, 
construct validity and content validity (20). 
 
Criterion validity  
Criterion validity is usually defined as the extent to which scores of an instrument are 
related to a criterion measure, i.e. a measure of the target construct that is widely 
accepted as a valid representative of that construct (21). The criterion measure can be a 
previously validated instrument measuring a similar construct, or a clinical variable that 
is conceptually related to the construct that the new instrument purports to measure. In 
headache research, the clinical characteristics of the individual’s headaches (such as the 
frequency, severity or duration of the attacks) are frequently used as criterion measures, 
and criterion validity is assessed by measuring the correlation of the patient’s headache 
characteristics with the questionnaire’s items, dimensions and total score.  
 
Construct validity 
Construct validity refers to an agreement between a theoretical concept (‘construct’) and 
the instrument designed for measuring it. The necessity of examining the construct 
validity of the instruments stems from the fact that an instrument can only examine the 
observable aspects of the construct. Convergent and discriminative validity are two 
subcategories of construct validity.   
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Convergent validity 
Convergent validity shows the correlation with another, already validated instrument. 
Correlation of the individual items, the dimensions and the total score can be analysed.  
 
Discriminative (known groups) validity 
Discriminative validity is measured by comparing the results of the instrument in two 
diagnostic groups. 
 
Content validity  
Content validity expresses the degree to which the underlying construct (QOL) is 
comprehensively sampled by the instrument’s items. Unlike other forms of validity, 
content validity cannot be formally tested, but is assured by (and can be judged by) the 
methods followed at the instrument’s development process (10). 
 
Responsivity  
Responsivity means that the instrument is able to follow and measure changes in the 
HRQoL (caused for example by a medical treatment).  
 
 
2.7 Validating an instrument in different languages 
 
A validated instrument can only be used in the original language in which the validation 
studies were done. Before using in another language, the instrument has to be validated 
in the new language. The first step in the translation process is that two independent 
“bilingual” translators translate the instrument into the target language. After that, the 
two translators’ versions are compared and a consensus version is created. This version 
is translated back into the original language by a further bilingual translator who did not 
have access to the original version, then the original and back-translated versions are 
compared for differences in content. In case of translation errors necessary changes are 
made to the final version on the target language. This final version is than pilot-tested in 
a small group of patients, to assess the intelligibility of the instrument.  If  the result is 
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good, the whole validation process (same as in the original instrument) has to be 
repeated in the new instrument (22). 
 
 
2.8 Burden of headache and measuring HRQoL in headache 
 
2.8.1 Introduction 
 
Headache is one of the most frequent complaints in medical practice, and it causes a 
significant burden both for the individual and for the society. The classification of the 
International Headache Society defines two groups of headache disorders: primary and 
secondary (symptomatic) headaches (23). Primary headaches are caused by the 
dysfunction of the structurally intact nervous system; they are characterized by 
stereotyped headache attacks which recover usually spontaneously after a time which is 
specific to the particular headache type. The diagnosis is based on a careful headache 
history (localization, intensity, characteristics, temporal relationships, accompanying 
symptoms, provoking and mitigating factors) and negative neurological examination. 
The most common primary headache is tension type headache (TTH), which global 
prevalence exceeds 40%, while the prevalence of migraine is approximately 12% (24). 
Cluster headache is one of the most intense human pain syndromes; its name denotes 
the characteristic grouping of headache attacks over a period that usually lasts some 
weeks and months (cluster episode) , which is then followed by a longer headache-free 
period. Its global prevalence is less than 1%, but its prevalence is over 5% in headache 
centers (25). About 2% of the population has medication overuse headache. This 
disorder develops from primary headaches, most often from migraine and it is hard to 
treat; its relative frequency is much higher in secondary and tertiary care (over 30% in 
headache centers) (26, 27). 
 
Primary headaches constitute a public health problem, affecting 46% of the adult 
population globally, causing a significant amount of disability (24) and poor health 
related quality of life (28). According to data from 2010, the third costly neurological 
disease in the European Union is primary headache. Migraine and medicine overuse 
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headaches are the most costly headaches (28). The importance of the most common type 
of primary headaches, tension-type headache, is due to its high prevalence, while cluster 
headache deserves attention due to the very intensive pain  (30). 
 
A representative epidemiological survey which includes several headache types has not 
been made in Hungary up to now, but according to moderate estimates at least 3.5 
million Hungarian people have regular headaches. Approximately 1 million Hungarians 
suffer from migraine, and the migraine-related economic loss due to lost work hours is 
about 15 billion Forints per year (based on a 80000 Forint minimum wage). The number 
of patients with episodic tension-type headache in Hungary is about 3 to 4 million, the 
number of patients with chronic tension type headache is about 2-300000, the number 
of patients who suffer from medication overuse headache is also approximately 2-
300000 and there live about 10,000 patients in the country who have cluster headache. 
For comparison, there are 30 accredited headache centers in Hungary, which treat 
approximately 20-30000 patients per year (30, 31). 
 
 
2.8.2 HRQoL instruments used in headache 
 
In the last 20 years, a number of studies were conducted about the effect of headache 
disorders on HRQoL. Depending on the purpose of these studies, different instruments 
were employed. Initial studies focused on the effect of migraine and other primary 
headaches on overall HRQoL, using generic instruments. Later, headache-specific 
instruments were developed and used both alone or in combination with generic 
HRQoL instruments and/or measures of disability. There is a significant amount of 
scientific evidence about the negative effect of episodic and chronic migraine, cluster 
headache (32-34), TTH (35) and chronic daily headache (36) on generic and headache-
specific QOL. The effects of acute and prophylactic (37, 38, 40-44) migraine treatment 
on QOL have also been documented.  
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2.8.2.1 Generic Instruments  
 
20-Item Short Form Health Survey (SF-20) 
This instrument was one of the two constructed to survey health status in a large 
representative study surveying health-related quality of life in the United States, i.e. the 
Medical Outcomes Study. As the name denotes, the questionnaire consists of 20 items. 
SF-20 measures physical, role and social functioning, mental health, pain and health 
perceptions; many of its questions are included in SF-36 but the latter also studies 
emotional role functioning and vitality and collects more information about physical 
functioning, physical role functioning and pain (39). In an early HRQoL study by 
Solomon et al, the SF-20 was used to measure quality of life in different headache types 
(migraine, cluster headache, tension-type headache and ‘mixed headache’). Pain scores 
were significantly worse in cluster headache patients than in migraineurs. Social 
functioning was worse in cluster and tension-type headache patients than in migraine 
patients. Mental health scores were worse in tension-type headache than in migraineurs. 
Physical functioning was worse in tension-type headache than in cluster headache (45) . 
 
36-Item Short Form Health Survey (SF-36) 
The SF-36 was also constructed to survey health status in the Medical Outcomes Study. 
It was designed for use in clinical practice and research, health policy evaluations, and 
general population surveys. The survey was constructed for self-administration by 
persons 14 years of age and older, and for administration by a trained interviewer in 
person or by telephone (46). The SF-36 is one of the most frequently used generic QOL 
instrument, it was validated in 50 countries. The SF-36 is a multipurpose, short-form 
generic health survey that yields an eight-scale profile of functional health and well-
being by asking only 36 questions. The eight health concepts measured by SF-36 were 
selected from 40 included in the Medical Outcomes Study (MOS) that used a 149-item 
Functioning and Well-Being Profile (47). The 36 items of SF-36 are aggregated in eight 
scores, each representing 2–10 items. Table 2 lists the names and definitions of these 
scores. Four items [physical functioning (PF), role physical functioning (RP), bodily 
pain (BP) and general health (GH)] represent physical health and four [vitality (VT), 
social functioning (SF), role emotional functioning (RE), mental health (MH)] are 
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related to mental health; accordingly, physical and mental composite scores can also be 
calculated (48). Extensive statistical testing proved that all items in each score met strict 
predefined criteria of convergent validity (i.e. each item was substantially related to the 
total score of that scale) and of discriminant validity (i.e. each item correlated 
significantly higher with its scale than with other scales) (49). Widely accepted as it is, 
the SF-36 is far from examining all notable aspects of QOL. Among other aspects, the 
SF-36 does not collect data about sleep and its quality, cognitive features, leisure 
activities, sexual life, self-confidence, worries, and the quality of interpersonal 
communication. As it is a generic measure, SF-36 does not gather data about symptoms 
or problems that are specific to one condition. Nevertheless, SF-36 was found to be a 
reliable and useful means of studying the functioning and well-being of patients, as 
testified by the high number of publications. In fact, a PubMed search done on 3
d
  
January 2015 retrieved  10241 publications mentioning “SF-36 quality life”. The 
original version of the SF-36 (also validated in Hungarian) does not calculate any 
dimensions or a total score. It measures only the scores of the eight domains, thus 
producing quality of life profiles which are often represented in graphical form. The 
later version, the SF-36v2 allows the calculation of physical and mental dimensions. 
Data collected with the first version can be converted to the second version only after a 
study on a large sample in the general population. This was not made for the Hungarian 
version, therefore the second version is not validated in Hungarian language (50).  
 
Studies with SF-36 have established that the impact of migraine on patients’ health 
status and quality of life may be similar or grater than that of chronic illnesses, such as 
osteoarthritis (37), diabetes (37), low back pain (38), depression (38, 39) or congestive 
heart failure (38). 
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Table 2. Structure of the SF-36 questionnaire. SF-36 measures eight health concepts. 
 
SF-36 
Full name Abbreviation Definition 
Physical functioning PF Extent to which health influenced physical activity 
(eg. sports) in the past 4 weeks 
Role physical RP Extent to which health influenced daily 
(workplace) activities in the past 4 weeks 
Bodily pain BP Extent of bodily pain experienced in the past 4 
weeks 
General health GH Overall ratings of current health in general 
Vitality VT Energy level and fatigue 
Social functioning SF Extent to which health influenced normal social 
activities in the past 4 weeks 
Role emotional RE Extent to which emotional problems influenced 
daily (workplace) activities in the past 4 weeks 
Mental health MH General mood or affect in the past 4 weeks 
 
 
2.8.2.2 Headache specific instruments 
 
Since the 1990s several headache-specific QOL instruments have been developed.  
These include the Migraine-specific Quality of Life Questionnaire (MSQ2.1) (51), the 
Migraine-Specific Quality of Life measure (MSQOL) (52), the 24-hour Migraine 
Quality of Life Questionnaire (24-hour MQoLQ) (53), the French Qualite´de Vie et 
Migraine (QVM) (54) questionnaire, and two questionnaires measuring related 
concepts: the Headache Impact Test (HIT-6) (55) measuring headache impact, and the 
Migraine Disability Assessment Score (MIDAS) (56) that measures migraine-related 
disability.  
 
The headache-specific QOL instruments were mainly developed to follow the status of 
migraineurs. Although they were used several times in other types of headache, most of 
them had not been validated in these headache types. Based on PubMed and Scopus 
searches, only MSQ2.1 and HIT-6 have been psychometrically validated for chronic 
migraine and MSQOL for TTH, but none have been validated in other headache types. 
The above mentioned instruments are briefly described below (Table 3). 
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Table 3. Headache specific HRQoL instruments List of abbreviations: M: migraine, EM: 
episodic migraine, CM: chronic migraine, TTH: tension type headache, CTTH: chronic tension type 
headache, CH: cluster headache, MOH: medical overuse headache, CDH: chronic daily headache 
 
Instrument Validation Used in other 
headache types 
without validation 
Endpoint 
Acut treatment Prophylactic 
treatment 
MSQOL M, TTH - - botulin toxin 
MQoLQ 
(24h MQoLQ) 
EM CM, „chronic 
headache” 
telcagepant 
rizatriptan 
(and so on) 
botulin toxin 
HIT-6 EM, CM TTH, CTTH, CH, 
MOH, CDH, 
fibromyalgic 
headache 
sumatriptan topiramate, 
botulin toxin  
(and so on) 
MSQ2.1 M, EM, CM CH, Trigeminal 
neuralgia 
sumatriptan, 
naproxen 
(and so on) 
beta blockers 
botulin toxin  
(and so on) 
QVM M TTH, CDH, other 
episodic 
headaches, CM 
sumatriptan 
naratriptan 
 
 
 
Migraine-specific Quality of Life Questionnaire (MSQ2.1) 
The MSQ2.1 is the current 14-item version of the former 16-item Migraine Specific 
Questionnaire. It measures three dimensions of headache impact: role-restrictive, role-
preventive and emotional function. Seven questions ask about the extent of limitation in 
daily activities caused by migraine (work, leisure activities, concentration, energy, etc). 
This is the MSQ’s so-called role-restrictive area. Four questions are about how often are 
these activities limited- this is the role-preventive domain. Three questions probe the 
emotional impact of migraine (feelings of frustration and helplessness). 
MSQ2.1 was found to be reliable and valid in assessing QOL in migraine and has been 
formally validated for patients undergoing prophylactic migraine treatment (40, 51). It 
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has also been used in cluster headache (33). More recently, MSQ2.1 was validated for 
clinical use in episodic and chronic migraine (57) and was found to demonstrate 
significant differences between these, with chronic migraine patients having lower 
values in all dimensions. 
 
Migraine-Specific Quality of Life measure (MSQOL) 
The MSQOL is a 25-item instrument that was found to be a valid and reliable measure 
for cross-sectional comparisons that encompass a migraine patient’s subjective well-
being (52). Further testing of the instrument revealed three dimensions (avoidance, 
relationships and feelings) and provided evidence for the calculation of total score (58). 
Interestingly, another group described a different structure of the MSQOL with four 
dimensions (physical, psychical, social and life rhythms) in a study of patients with 
migraine or tension-type headache (TTH) (58). The MSQOL has been successfully used 
as an outcome measure in prophylactic drug trials for migraine (41). 
 
24-hour Migraine Quality of Life Questionnaire (24-hour MQoLQ) 
The MQoLQ was developed to measure the acute changes in QOL in migraineurs 
during a migraine attack. The questionnaire has 15 items grouped in five domains: work 
functioning, social functioning, energy, feelings/concerns, and migraine symptoms. In 
the validation study the domains showed good internal consistency and construct and 
discriminant validity, and responsiveness to acute migraine attacks. It detected 
significant changes of QOL during the acute migraine attack. Moderate to strong 
negative correlations were found between QOL and headache severity, limitations of 
activity, number of migraine symptoms, and headache duration (53). The MQoLQ was 
validated and primarily used among migraineurs, but also as an endpoint in drug trials 
(43), and it was found to be useful in the long-term follow-up of chronic headache 
patients (60). The MQoLQ showed significant improvement of QOL during an acute 
migraine attack in a randomized, triple-blind, placebo-controlled clinical trial with 
rizatriptan for acut migraine treatment (43). 
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QVM (Qualite´de Vie et Migraine)  
QVM is a French migraine-specific QOL instrument, with four domains: psychological, 
somatic, social repercussion and disturbance generated by the treatment (54). In the 
validation study, the reliability assessed by test–retest reproducibility was good (r_0.70–
0.80). In a later study on a nationwide sample, frequency, severity and treatment 
resistance of headaches, as well as headache-related disability, were significantly 
correlated with QVM’s total score and subscales; correlation coefficients were not 
reported (61). QVM was used in many French studies, including acute drug trials in 
migraine (44) and also in patients with chronic daily headache (61) and TTH (62). The 
use of sumatriptan nasal spray 20 mg for the treatment of migraine attacks during a 12 
week period was associated with a significant improvement in migraine patients' quality 
of life measured by the QVM (44). 
 
Headache Impact Test (HIT-6) 
In 2003 the 6-item Headache Impact Test (HIT-6) was introduced. HIT-6 is an 
instrument designed to measure headache impact, a concept that is strongly related to 
QOL (55). The HIT-6 covers six content categories represented in widely used surveys 
of headache impact, including social and role functioning, vitality, cognitive functioning 
and psychological distress. It was developed using an existing item pool of 54 items and 
from 35 items suggested by clinicians, using advanced methods of item response theory. 
In a large study, HIT-6 was found to be efficient, reliable and valid for the screening 
and monitoring of patients with headache (63). Subsequently, it has been extensively 
used in clinical practice, and applied in studies measuring headache impact and also in 
drug trials in migraineurs. The HIT-6 has been validated in episodic and chronic 
migraine (63). It has also been used in chronic daily headache (64) and TTH (65). 
 
Migraine Disability Assessment Score (MIDAS)  
MIDAS is a five item headache-specific tool designed to assess headache-related 
disability on three activity domains (paid work, household work, social/family 
activities). It was developed to improve doctor-patient communication about the 
functional consequences of migraine (56). MIDAS is able to detect difference in 
disability between migraine without aura and chronic migraine. Different values were 
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measured also, when migraine and tension type headache were compared. Gesztelyi et 
al found that the MIDAS scores were higher for patients with tension type headache in 
association with migraine, than those who did not have migraine (66). 
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3. Aims  
 
The Headache Group of the Department of Neurology, Semmelweis University has 
systematically collected data for more than 10 years about the clinical features of 
headaches. A significant part of our research investigated the impact of primary 
headaches on HRQoL. In my PhD thesis, I present the results of these studies. 
 
The aim of or studies was to assess the impact of common headache types on HRQoL. 
First, we investigated the health-related and condition-specific quality of life in episodic 
cluster headache. Second, we aimed to develop a new comprehensive headache-specific 
questionnaire, which assesses several aspects of QOL and which is useable in common 
headache types.  
 
We then examined the psychometrical properties of our new questionnaire, called 
Comprehensive Headache-related QOL Questionnaire, in several headache types. We 
tested the new questionnaire in migraineurs, tension type headache patients and medical 
overuse headache patients. To assess the responsiveness of the Comprehensive 
Headache-related QOL Questionnaire for following QOL of headache patients during 
headache treatment we tested the questionnaire on a sample with medication overuse 
headache. 
During these studies, our hypotheses were the following: 
1. Cluster headache patients during the active phase have lower general and 
headache-specific QOL than migraineurs. 
2. After the termination of the cluster episode the patients’ general and headache-
specific QOL improves significantly. 
3. The new comprehensive headache-specific QOL instrument will show adequate 
reliability and validity in migraine and tension type headache.  
4. The comprehensive headache-specific QOL instrument will also show adequate 
psychometric properties in medication overuse headache. 
5. The prophylactic treatment of medication overuse headache will result in better 
clinical endpoints, which will be paralleled by better QOL as measured by the 
new QOL instrument.  
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4. Methods 
 
4.1 Common elements of the studies  
 
4.1.2 Patients   
 
Outpatients, consecutively visiting the headache center of the Department of Neurology, 
Semmelweis University, who fulfilled the International Headache Society (IHS) criteria 
(23) for migraine with and without aura (episodic type; ICHD-II codes 1.1 and 1.2) or 
tension type headache (either episodic or chronic; ICHD-II codes 2.1–2.3) or episodic 
cluster headache (ICHD-II code 3.1.1) or medication overuse headache (ICHD-II code 
8.2.) took part in the studies. During the psychometric testing of the draft version of the 
Comprehensive Headache-related QOL Questionnaire data of 25 outpatients visiting the 
headache center of the National Institute of Neuroscience with the diagnosis of episodic 
migraine were also included. 
 
In all studies, we excluded patients suffering from the rare adult migraine subtypes 
(hemiplegic migraine, basilar-type migraine, retinal migraine and complications of 
migraine (ICHD-II codes 1.2.4–1.2.6, 1.3–1.5). According to the IHS criteria, patients 
meeting one of the sets of criteria for probable tension type headache (ICHD-II. code 
2.4) may also meet the criteria for one of the subforms of probable migraine (ICHD-II. 
code 1.6), therefore we also excluded patients with the diagnosis of probable migraine 
and probable tension type headache in order to minimize the chance of misdiagnosing 
the patients. Patients with significant somatic or mental diseases were excluded (e.g. 
concomitant chronic pain syndromes, untreated hypertension, and untreated or severe 
kidney or liver disease). Other concomitant treated disorders were not excluding 
criteria, but their possible effect on QOL was not taken into account in the statistical 
analysis.  Mild to moderate depression was not an exclusion criterion. The more 
detailed description of the patients taking part in the studies can be found in the 
respective chapters. The studies were approved by the Regional and Institutional 
Committee of Science and Research Ethics of Semmelweis University. 
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4.1.2 Data recording 
 
Generic QOL was measured with the validated Hungarian version of the SF-36 
questionnaire (67) in all studies. Headache-specific quality of life was measured with 
MSQ2.1 in the first study, which investigated the health-related and condition-specific 
quality of life in episodic cluster headache. In the other studies, after our working group 
developed the new Comprehensive Headache-related QOL Questionnaire, headache-
specific quality of life was measured by this new instrument.  
 
The patients completed the questionnaires in the Headache Unit, after their outpatient 
visit; the questionnaires were administered by the headache specialist seeing outpatients 
on the given day. The questionnaires were filled in on the spot and given back to the 
staff. Missing data were not complemented.  
 
The patient’s headache characteristics and other clinical data were recorded during their 
outpatient visit. Headache severity was assessed by the patient (visual analogue scale 
(VAS); 0–100mm) and also by the specialist during the clinical interview (IHS rating 
scale, 0=pain free, 1=mild, 2=moderate, 3=severe). Headache diagnoses were made by 
the same headache specialists during the outpatient visit, using the IHS criteria. 
Depression was not formally tested during the visit. The HRQoL data were not used in 
the diagnostic and therapeutic evaluation of the patients during their medical visits.  
 
 
4.1.3 Methods 
 
Statistics were calculated using Statistica software, versions 8.0 to 11.0. The level of 
significance was set to p<0.05. As the data distribution of most HRQoL domains was 
not Gaussian, we used nonparametric tests in all studies. Wilcoxon signed rank tests 
were used to check differences within the groups. Spearman’s non-parametric tests were 
used to check for correlation between the QOL instruments and between HRQoL scores 
and patient characteristics. Differences between groups were assessed with either 
Kruskal–Wallis ANOVA with Dunn’s multiple comparisons tests or Mann–Whitney 
tests. 
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4.2 Examination of health-related and condition-specific quality of life in episodic 
cluster headache 
 
4.2.1 Background and objective 
 
Cluster headache (CH) is characterized by recurrent unilateral attacks of severe 
headache, accompanied by local signs and symptoms of cranial autonomic dysfunction 
(23). CH attacks may occur several times throughout the day over periods of several 
weeks. The stabbing, often excruciating pain can disrupt the daytime activity both at the 
workplace and in the family setting. Leisure and social activities may also be affected. 
The night-time occurrence of attacks can lead to sleep deprivation, which further 
degrades performance (68). Personal accounts of patients underline these considerations 
(69). While HRQoL in migraine and chronic headaches was widely studied, the effects 
of CH received much less attention. In our first study about HRQoL in headache we 
therefore set out to assess overall and disease-specific HRQoL in episodic CH patients, 
using a generic and a headache-specific instrument. 
 
 
4.2.2 Methods 
 
Patients 
Thirty-five patients with episodic cluster headache were involved in the study. The 
general inclusion and exclusion criteria were the same as described in chapter 4.1.2. 
Moreover, CH patients also having other significant headaches (migraine, chronic or 
frequent episodic tension-type headache, chronic daily headache) were not included in 
this study. The results were compared with those of a group of migraineurs (n=53) and a 
control group from the general population (n=62) who did not have migraine, cluster or 
daily headaches. Both comparator groups were matched for sex and age. A detailed 
description of the groups is to be found in Results (chapter 5.1). 
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Methods  
All patients completed the Hungarian versions of the generic HRQoL instrument SF-36 
and MSQ version 2.1.The patients filled in the questionnaires during their first visit due 
to the new CH period. At least 3 months after the termination of the CH period 
telephone interviews were used to clarify the health status of the patients and then 
follow-up questionnaires were sent to them by mail. In order to make data comparable 
we changed the word “migraine” to “headache attack” in MSQ2.1 in all three study 
groups. As in non-medical Hungarian usage ’migraine’ is used interchangeably with’ 
(severe) headache attack’, we felt that this change would not compromise the study. 
Moreover, head pain is probably the most important source of migraineurs’ limitations, 
as suggested by a study from Santanello et al, where rapid, complete, and sustained pain 
relief were shown to be the main determinants of HRQoL (70). The high frequency of 
’migrainous’ headache accompaniments (nausea, vomiting, photo- or phonophobia) 
found in our CH sample (see Table 7), similar to those observed by Bahra et al. (71), 
further decreased the possibility that the different accompanying symptoms of CH and 
migraine would cause large scale-differences in HRQoL. Although we were not aware 
of MSQ2.1 being used in conditions other than migraine, we thought that its application 
in the CH sample was justified and MSQ2.1 scores of CH patients and migraineurs 
could be compared. 
 
 
4.3 Development and validation of the Comprehensive Headache-specific Quality 
of life Questionnaire 
 
4.3.1 Introduction 
 
There are some observations that raise the possibility that the previously used QOL 
instruments do not fully capture headache patients’ perceptions. As already mentioned, 
despite the obvious differences in the clinical picture and the patients’ complaints, there 
were only a few differences between the generic QOL profiles of migraine, cluster 
headache and TTH (45). In our first study, the SF-36 profiles of migraine and cluster 
headache were also surprisingly very similar. Although CH patients had lower scores 
than migraineurs on most scales, the difference was significant only on SF-36 scores 
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measuring bodily pain and social functioning. The headache-specific MSQ2.1 also 
failed to show any difference between the QOL profiles of cluster headache patients and 
migraineurs in this study (33).   
 
Patients may also feel that the instruments do not capture some important areas of their 
QOL, as was the case of our patients (suffering from cluster headache or migraine) 
during the above-mentioned trial (33). Moreover, a clinically effective therapy is not 
necessarily reflected by an improvement of the QOL scores of migraineurs (85).  
 
Besides these observations there is a methodological caveat when using headache-
specific QOL instruments. As discussed in chapter 2, the headache specific instruments 
were mainly developed for, and validated in migraineurs.  
 
Taken together, these limitations suggested that an instrument probing several important 
facets of life and validated in different headache types might provide patients and 
healthcare providers with more precise information about QOL in headache. In order to 
test this hypothesis, we have decided to develop a comprehensive headache-specific 
questionnaire in Hungarian language, assessing several aspects of QOL.  
 
 
4.3.2 Development process of the new headache-specific questionnaire 
 
We followed the recommendations outlined in (10) and (20) during the development 
phase of CHQQ. The development of the questionnaire consisted of the following steps 
(Table 4):  
 
1. relevant item identification  
2. development of a draft version 
3. psychometric testing of a draft version and development of the final version 
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Table 4. Development process of the new headache-specific questionnaire 
 
Step Source / Population 
 
Relevant item 
identification 
 
Creating a question pool 
Literature 
Headache experts (5) 
Open interviews Headache patients (25) 
Psychometric testing of the 25-item draft version  Migraineurs (117) 
Validation of the 23-item final version Migraineurs (168) 
TTH (34) 
MOH (68) 
 
 
4.3.2.1 Relevant item identification  
 
 First one of our team conducted open interviews with 25 persons suffering from the 
most important primary headache types (10 migraine, 10 TTH and 5 cluster headache 
patients). The questions for these interviews were based on the experience of five 
clinicians and literature reviews of QOL in headaches and other pain conditions. A 
question was considered a potential item if at least two clinicians and two patients from 
each diagnostic group felt the respective issue was important. Twelve of the 37 original 
questions were found redundant or insignificant and therefore removed, resulting in a 
25-item draft version. Consequentially, the items included in the final version were the 
ones that were meaningful both for the patients and the clinicians involved (86).  
 
 
4.3.2.2 Development of a draft version 
 
In a second step, 11 migraineurs from a larger group studied for the effect of migraine 
(87) were asked to complete the draft version and were then interviewed about it. These 
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interviews were used to determine whether each individual understood the items, felt 
them meaningful and whether they felt the answer categories were sufficient. Minor 
changes of content and format were applied accordingly. 
 
 
4.3.2.3 Psychometric testing of a draft version, and the development of the final 
version 
 
The 25-item questionnaire was tested in a group of 117 migraineurs and quality criteria 
for item selection applied (29). There was no ceiling effect in the sample. One item 
asking about the influence of headache on parental responsibilities (‘How much do your 
headaches interfere with your role as a parent?’) had by far the biggest proportion of 
missing answers (31% of the sample; mostly patients with grown-up children or no 
children) and therefore was not included in the final version. An item about prophylactic 
medication use (‘How often have you used prophylactic treatment for your headaches?’) 
had a very low (0.214) item-total correlation. Analysis of the clinical data revealed that 
beside those who regularly took a prophylactic medicine, a significant part of the study 
population considered the early administration of acute medications as ‘prophylactic’ 
treatment. This item was also problematic because taking a migraine prophylactic is the 
joint decision of the patient and the physician and therefore it is less likely to reflect the 
patient’s QOL. Therefore this item was also omitted from the final version of the 
questionnaire.  
 
The reliability and validity assessments confirmed that the resulting 23-item 
questionnaire was adequate for further testing. Reliability was assessed by internal 
consistency, measured by Cronbach’s α of all items. The questionnaire demonstrated 
good reliability, with Cronbach’s alpha being 0.893. Convergent validity was examined 
by calculating the correlation of the items with subscales of the SF-36 measure. 
Convergent validity was adequate; most “physical” items of the new questionnaire 
showed significant correlations with the bodily pain and role physical SF-36 subscales 
and most “psychical” and “social” items were correlated with mental health and social 
functioning SF-36 subscales. The correlation of the patients' migraine characteristics 
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with the questionnaire's items was used to assess criterion validity. Criterion validity 
was adequate, with headache severity being correlated with most of the items (29).  
 
Exploratory factor analysis with varimax rotation found that a single factor accounted 
for 47% of the total variance, while a second factor was responsible for 3.7%, and 
further factors accounted for even smaller amounts of variance: this was interpreted as 
the basis of calculating a total score (88). In the preliminary study we grouped the items 
according to the classical dimension structure used in QOL research (physical, mental 
and social), relying on the content of the items. This is considered a valid approach. 
Clinically useful scales are sometimes organized into subscales according to rational 
(rather than mathematical) principles and the two do not necessarily coincide. An 
example is the Headache Disability Inventory (89), where the authors rationally 
organized items into emotional and functional subscales; in a later study by Holroyd et 
al. the factor analysis of HDI items revealed that all items loaded on a single factor (90). 
Different studies may find a different underlying structure within the same instrument, 
as exemplified by the MSQOL, which was found to have three dimensions (avoidance, 
relationships and feelings) in an American study (58), and four dimensions (affective, 
social, energetic and life rhythms) in a Hungarian one (59). 
 
 
4.3.2.4 Description of the Comprehensive Headache-related QOL Questionnaire 
 
The 23-item QOL questionnaire, hereafter referred to as the Comprehensive Headache-
related QOL Questionnaire (CHQQ), examines the impact of headache on QOL in 
detail. The questions cover the 4 weeks before the data recording. All questions have 
five possible answers (5-point Likert scale), ranging from the absolute absence of 
restriction to maximal restriction. After scoring, the values are transformed to a 0–100 
point scale, the absence of restriction being equal to 100 points and the full restriction to 
0 points. Total score and the three dimensions (physical, mental and social) are 
calculated; they are the mean values of the relevant transformed item scores, i.e. the 
item scores are not weighted. It is also possible to use the questionnaire as a profile, in 
this case the scores of each item should be represented in graphical form. This can be 
useful among others to assess the effectiveness of a special therapy  (29, 113). 
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4.4 Validation of the Comprehensive Headache-specific Quality of life 
Questionnaire  
 
4.4.1 Validation in migraineurs and tension type headache patients              
 
4.4.1.1 Objective 
 
The aim of the study was to assess the psychometric properties of the headache-specific 
questionnaire on a large group of headache patients suffering from migraine and TTH. 
The main hypotheses were the following: 
1.  The questionnaire’s internal consistency will be adequate (Cronbach’s alpha 
>0.7) in the total sample and both headache types. 
2.  The individuals’ QOL, as indicated by the items, domains and total score, will 
be negatively correlated with clinical characteristics of their headache. 
3.  The new questionnaire’s items, domains and total score will be positively 
correlated with the relevant domains of the SF-36 measure. 
4.  Patients with TTH will have a better QOL (higher scores on the instrument) 
than patients suffering from migraine. 
 
 
4.4.1.2 Methods  
 
Patients  
A total of 202 patients suffering from migraine (n=168) or tension-type headache (TTH) 
(n=34) were involved in the study. Consecutive outpatients visiting the headache center 
of the Department of Neurology, Semmelweis University, in 2008–2010, who fulfilled 
the International Headache Society (IHS) criteria (23) for migraine with and without 
aura (episodic type; ICHD-II codes 1.1 and 1.2) or TTH (either episodic or chronic; 
ICHD-II codes 2.1–2.3) took part in the study. We excluded patients suffering from the 
rare adult migraine subtypes and those whose analgesic consumption reached the 
criteria of analgesic abuse (91). Patients with the diagnosis of probable migraine and 
probable TTH were also excluded to minimize the chance of misdiagnosing the patients. 
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All patients had headache as the main complaint at the time of the study. For general 
inclusion and exclusion criteria see chapter 4.1.2. 
 
Data recording 
The patients all completed the validated Hungarian version of the SF-36 and the CHQQ 
in the Headache Unit, after their outpatient visit; the questionnaires were administered 
by the headache specialist seeing outpatients on the given day. The questionnaires were 
filled in on the spot and given back to the staff. Missing data were not complemented. 
The patient’s headache characteristics and other clinical data were recorded on the same 
day, during their clinical interview. Headache severity was assessed by the patient 
(visual analogue scale (VAS); 0–100mm) and also by the specialist during the clinical 
interview (IHS rating scale, 0=pain free, 1=mild, 2=moderate, 3=severe). Headache 
diagnoses were made by the same headache specialists during the outpatient visit, using 
the IHS criteria. Depression was not formally tested during the visit. As this was a 
validation study, the data were not used in the evaluation of the patient’s functional 
status, disease severity or therapeutic needs.  
 
 
Methods 
To assess the reliability of our questionnaire, we calculated the Cronbach’s alpha for the 
whole instrument and its dimensions. We used several methods to assess the validity of 
the instrument. First we examined the correlation of the patients’ headache 
characteristics with the questionnaire’s items, dimensions and total score (criterion 
validity). We then examined the correlation of the individual items, the three 
dimensions and the total score with the domains of the SF-36 measure, a means of 
assessing convergent validity. In these analyses the degree of correlation was measured 
by calculating Spearman’s rank correlation coefficients. We also assessed 
discriminative (known groups) validity, by comparing the results of the instrument in 
the two diagnostic groups, M and TTH, using Mann–Whitney tests. In order to assess 
the structure of the instrument we performed an analysis of item-dimension correlations 
using Spearman’s rank correlation coefficients. Statistics were calculated using 
Statistica software, version 8.0. The level of significance was set to p<0.05. 
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4.4.2 Validation in medication overuse headache 
 
4.4.2.1 Introduction   
 
Medication overuse headache (MOH) affects 1 to 2% of the population (26), and may 
be found in as many as 30% of patients seen at tertiary headache centers (27). It 
hallmarks are frequent headache, and the presence of medication overuse, the latter 
being instrumental in the development or worsening of the headache (103). Medication 
overuse headache is associated with a poor health-related quality of life. As reviewed by 
Lanter-Minet et al., the generic QOL instrument SF-36 consistently showed lower 
scores for patients with chronic daily headache (CDH) and medication overuse 
compared to patients with CDH but without medication overuse or patients with 
episodic headache in both patients recruited from headache specialty centers and also in 
samples from the general population (103). On the other hand, it is worth mentioning 
that the previously used generic and headache-specific QOL instruments have not been 
formally validated in MOH, and therefore these data may not reflect the burden of 
MOH. This chapter reports our as yet unpublished data about the validation of CHQQ in 
medication overuse headache.  
 
 
4.4.2.2 Objective  
 
To assess the psychometric properties of CHQQ in patients diagnosed with MOH. 
 
4.4.2.3 Methods   
 
Patients  
We involved 68 MOH patients (53 women and 15 men; mean age 42.1 ± 14.2 years), 
followed up at the Department of Neurology, Semmelweis University. The majority of 
the patients had a clinical headache diagnosis of chronic migraine (51 patients, ie. 75%); 
15 had chronic tension type headache and two had chronic daily headache not otherwise 
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specified. Forty-four patients (65%) were overusing simple NSAIDs, 11 combined 
NSAIDs, while 10 had triptan-, and 3 ergot-overuse at the time of the study. The 
detailed inclusion and exclusion criteria were the same as described in chapter 4.1.2. 
 
Data recording 
As in the previous studies, the patients completed the CHQQ instrument and the 
validated Hungarian version of the SF-36 generic QOL instrument during their 
outpatient visits.  The questionnaires were administered by the headache specialist 
seeing outpatients on the given day. The questionnaires were filled in on the spot and 
given back to the staff. Missing data were not complemented.  
The patients’ headache characteristics and other clinical data were recorded during their 
clinical interview at the same outpatient visit. Headache severity was assessed by the 
patient (visual analogue scale (VAS); 0–100mm) and also by the specialist during the 
clinical interview (IHS rating scale, 0=pain free, 1=mild, 2=moderate, 3=severe). 
Headache diagnoses were made by the same headache specialist during the outpatient 
visit, using the IHS criteria. Depression was not formally tested during the visit. The 
QOL data were not used in the evaluation of the patient’s functional status, disease 
severity or therapeutic needs.  
 
Statistical methods  
The validation process was similar to the validation of the CHQQ in migraine and 
tension type headache (see chapter 4.4.1.2). Briefly, we assessed the reliability of the 
questionnaire by calculating the Cronbach’s alpha for the whole instrument and its 
dimensions. The validity of the instrument was examined by assessing its criterion 
validity (the correlation of the patients’ headache characteristics with the 
questionnaire’s items, dimensions and total score), convergent validity (the correlation 
of the items, dimensions and total score with the domains of the SF-36 questionnaire), 
and discriminative validity (comparing the results of the instrument in the two 
diagnostic groups, MOH and chronic tension type headache). Correlations between the 
SF-36 and the clinical data were also calculated for comparisons between the two 
instruments’ criterion validity. Statistics were calculated using Statistica software, 
version 11.0. The level of significance was set to p<0.05. As the data distribution of 
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most HRQoL domains was not Gaussian, we used nonparametric tests in all studies. 
When assessing criterion and convergent validity, the degree of correlation was 
measured by calculating Spearman’s rank correlation coefficients. We also assessed 
discriminative (known groups) validity, by comparing the results of the instrument in 
the two diagnostic groups, MOH and chronic tension type headache, using Mann–
Whitney tests. Statistics were calculated using Statistica software, version 11.0. The 
level of significance was set to p<0.05. 
 
 
4.4.3 Examination of responsivity in medication overuse headache 
 
4.4.3.1 Introduction   
 
Medication overuse headache is notoriously difficult to treat. There is a growing 
consensus that the basic requirement of its treatment is detoxification (withdrawal 
therapy) supplemented by adequate preventive measures (106). Depending on the 
pharmacological type of overused medication and also on the organization of the 
healthcare facility, both in-, and outpatient treatment programs have been advocated. 
The current evidence suggests that both settings may be adequate. There is moderate 
evidence that topiramate is an effective prophylactic option for MOH, while 
corticosteroids and amitryptiline are possibly effective (106). Recently, a subgroup 
analysis of medication overusers among chronic migraine patients participating in the 
PREEMPT study demonstrated that onabotulinum toxin was also effective (104), a 
finding that had also been substantiated in an independent Italian study (107). It was 
demonstrated that the SF-36 and the headache-related disability tool, MIDAS (Migraine 
Disability Assessment Score) were sensitive to the effect of treatment (108). Two 
studies found that low SF-36 scores may be predictors of treatment outcome. In an 
Austrian study of an inpatient withdrawal program, poor mental SF-36 composite scores 
at baseline correlated with frequent headaches at follow-up (109). A Norvegian study 
following 80 MOH patients for one year found that lower scores on the Bodily Pain and 
General Health Perception domains of the SF-36 were associated with poor outcome 
(110). It was suggested that the SF-36 may be used as a predictor of outcome of 
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withdrawal therapy in MOH. Headache-specific QOL instruments were employed less 
frequently in MOH, mostly in longitudinal studies about the effect of treatment (104, 
111, 112).  In a placebo-controlled randomized study about topiramate as a preventive 
agent of chronic migraine, 78% of the patients met the criteria of MOH. In this study, 
various PROs including the MSQ2.1, HIT-6 and MIDAS were used. From an intent-to-
treat population of 59, only 38 patients finished the study. Topiramate significantly 
reduced the mean number of monthly migraine days. MIDAS showed improvement in 
the verum group, but there were no significant differences between the two groups’ 
HIT-6 and MSQ2.1 scores (111). In a small randomized, double-blind, active-
controlled, crossover trial, nabilone proved superior to ibuprofen in reducing the 
severity and frequency of headache, the quantity of analgesic intake and in increasing 
the quality of life as measured by the generic SF-36 QOL questionnaire and also 
decreasing headache impact measured by the HIT-6. The changes in SF-36 and HIT-6 
scores were small but statistically significant (112). Finally, in a subgroup analysis of 
the PREEMPT trial database, the effect of onabotulinumtoxin A on chronic migraine 
patients with acute headache medication overuse was studied. The endpoints included 
changes in HIT-6 and MSQ2.1. Both instruments showed significant improvement in 
the active group as compared to the placebo group (104).   
 
 
4.4.3.2 Objective   
 
The aim of this pilot study was to assess the feasibility of using CHQQ as an outcome 
indicator in a group of patients suffering from medication overuse headache. Our main 
hypotheses were the following:  
 
1. The questionnaire will show low QOL values before treatment of MOH. 
These values will be lower than those of episodic migraine patients studied in 
the same headache center.     
2. The patients’ headache characteristics will improve after the treatment.  
3. The patients’ quality of life (individual items as well as domains and total 
score) will also improve after the treatment.  
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4. The improvement of quality of life will show mild to moderate correlations 
with the improvement of headache characteristics.  
 
 
4.4.3.3 Methods 
 
Patients 
Consecutive patients with headaches fulfilling the diagnostic criteria of MOH (91) were 
involved. Mild to moderate depression was not an exclusion criterion, but due to the 
small number of patients was not taken into consideration as a grouping variable. The 
detailed inclusion and exclusion criteria were the same as in chapter 4.1.2. On the 
whole, our sample consisted of 15 MOH patients. The quality of life of the MOH 
patients at baseline was compared to our previously obtained QOL values of 177 
patients suffering from episodic migraine (EM). The demographic and selected clinical 
data of the MOH patients and the control group of episodic migraineurs are summarized 
in Table 5.  
 
Table 5. Demographic and clinical data of the study participants. Data are presented as 
mean ± SD if not otherwise indicated. VAS: Visual analogue scale. MOH: medication overuse 
headache 
 
 MOH patients Episodic migraineurs 
Mean age (years) 39,7 ± 12,5 34,9± 11,2 
Gender  Female: 13 
Male: 2 
Female: 156 
Male: 21 
Primary headache type Migraine without aura: 13 
Tension type headache: 2 
Migraine without aura: 
139 
Migrane with aura: 38 
Mean number of headache 
days per  month 
24,3 ± 5,7 4,4 ± 2,2 
Mean pain intensity (VAS) 67 ± 13,6 70,7 ± 18,0 
Number of patients 
overusing different types 
of analgesics 
Simple NSAID: 6 
Combined NSAID: 2 
Triptan: 7 
not applicable 
Mean analgesic dose per 
month 
Simple NSAID: 59,6 ± 44,6 
Combined NSAID: 28,5 ± 9,2 
Triptan: 19,3  ± 5,0 
not recorded 
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Treatment / Intervention 
The patients were enrolled to a complex treatment program consisting of acute 
medication withdrawal, preventive pharmacological treatment, structured advice and 
lifestyle intervention. All patients were offered the possibility of an in-patient first 
phase: seven of them opted for it, the others were excusively treated as outpatients. For 
those who preferred it, the inpatient period lasted 7 to 10 days. The demographic and 
clinical data of the inpatient and outpatient groups were not significantly different 
(Table 6). 
 
Table 6. The clinical characteristics and baseline QOL values of the in-, and outpatient 
groups. There were no significant differences in this sample (Mann-Whitney tests or 
Fisher’s exact tests). VAS: Visual analogue scale. 
 
 Inpatients Outpatients p value 
Mean age (years) 43,6 ± 12,4 36,4± 12,3 0,3244 
Gender (F/M) Female: 5 
Male: 2 
Female: 8 
Male: 0 
0,2000 
Primary headache 
type 
Migraine without aura: 6 
Tension type headache: 1 
Migraine without aura: 7 
Tension type headache: 1 
1,000 
Mean number of 
headache days per  
month 
26,4 ± 5,4 22,4 ± 5,6 0,2147 
Mean number of 
attacks per  month 
25,9 ± 5,1 21,8 ± 6,3 0,2408 
Mean pain intensity 
(VAS) 
69,1 ± 13,2 63,6 ± 14,1 0,3541 
Number of patients 
overusing different 
types of analgesics 
Simple NSAID: 3 
Combined NSAID: 1 
Triptan: 3 
Simple NSAID: 3 
Combined NSAID: 1 
Triptan: 4 
1,000 
Mean analgesic dose 
per month 
50 ± 40,2 20,2 ± 5,7 0,0822 
 
 
Prophylactic medications were chosen according to the primary headache type, the 
patients’ previous experience with headache prophylactics, and individual 
contraindications or allergies. The most commonly used prophylactics were valproic 
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acid and tricyclic antidepressants (amitriptyline or clomipramin); onabotulinum toxin 
was administered to three. Controlled quantities of naproxen and/or paracetamol were 
used as acute medications.  
 
Structured advice was given about the patients’ headache, the role of medication 
overuse in the chronification of headaches in general, the importance of the withdrawal, 
the possibilities of acute and prophylactic medication use during the study period, and 
the possible difficulties of the withdrawal phase. Lifestyle intervention was aimed at 
helping the patients establish a more balanced daily and weekly rhythm (of work, meals, 
sleep and leisure activities) and identifying and reinforcing individual strategies of 
coping.  
 
Data recording  
Clinical data were collected using a detailed headache diary which is routinely used in 
our Headache Service. Patients were asked to record all their headaches, regardless of 
the severity or length of the attacks. Information was requested about the duration, 
quality and severity of the head pain, about the accompanying symptoms, and also 
about the type and dose of acute pain medications. As the patients had already been 
followed at our outpatient service before the actual study, the patients’ diaries also 
contained the relevant clinical data from the month before the actual treatment. The 
average headache severity was assessed by the patient (VAS; Visual Analogue Scale 0-
100 mm continuous version) on a sheet accompanying the CHQQ, and also by the 
headache specialist during the clinical interview (International Headache Society Rating 
scale, 0=pain free, 1=mild, 2=moderate, 3=severe). The CHQQ was completed at the 
beginning of the treatment period and at the end of the second month of treatment.  
 
Methods 
The statistical analyses were performed using Graphpad Prism 4.0. As some of the data 
were not following a normal distribution, we used nonparametric tests throughout the 
study (Mann-Whitney tests for comparing the MOH and EM group, Wilcoxon tests for 
the comparison of baseline and post-treatment clinical and QOL values, and Spearman’s 
tests to look for correlations between the change in clinical characteristics and QOL). 
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When analyzing the correlations between the improvement of clinical variables and 
QOL, the improvement was expressed as the percentage of the baseline value, ie. 
improvement = (baseline value – post-treatment value) x100.   
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5. Results 
 
5.1. Examination of health-related and condition-specific quality of life in episodic 
cluster headache  
 
Patient characteristics 
A total of 35 CH patients were studied. Twenty-four (69%) did not have any relevant 
medical condition other than CH. Eleven patients (31%) also had other health problems, 
including five cases with medically treated hypertension, three with mild depression, 
one with low back pain and one with essential tremor. One patient had Type 2 diabetes 
mellitus, while one of the hypertensive patients had a mild degree of leukoaraiosis 
confirmed by magnetic resonance imaging. The majority of CH patients did not receive 
prophylactic treatment at the time of the study. In five, prophylactic verapamil treatment 
had already been started, but they were still experiencing daily attacks. Only 11 (31/%) 
of the 35 used subcutaneous sumatriptan as abortive agent; other options were oxygen, 
indomethacin or soluble non-steroidal anti-inflammatory drugs. The infrequent use of 
sumatriptan was due to financial issues (the local health system covered only 50% of its 
price at the time of the study). The demographic data of the patient groups is presented 
in Table 7. The two comparator groups were matched to the CH group for sex and age. 
There was no significant difference in disease duration and percentage of sumatriptan 
users in the CH and migraine groups. The percentage of depressed patients was 
significantly greater and that of hypertensive patients somewhat smaller in migraineurs; 
the concomitant disease profile in the headache-free control group was similar to the 
CH group. 
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Table 7. Demographic data of CH patients. Data are expressed as mean ± SD if not 
otherwise indicated  
 
Age 44.73 ± 14.71 years, range 21-76  
Gender ratio (male : female) 25 : 10 
Disease duration  12.72 ± 9.26 years, range 1-32 
Duration of present episode 5.48 ± 3.46 weeks, range 2-17 
Number of attacks per day  1.74 ± 0.81, range 0.5-4 
Night-time attacks (yes : no) 28 : 7 
Nausea and/or vomiting (yes : no) 18 : 17 
Photophobia and/or phonophobia (yes : no) 21 : 14 
Smokers vs non-smokers 31 : 4 
Acute treatment  
(sumatriptan : oxygene : other) 
11 : 7 : 17 
Prophylactic treatment (yes : no) 5 : 30 
 
 
Generic HRQoL 
During the cluster period, CH patients had lower scores in all SF-36 domains than non-
migrainous controls. The difference was statistically significant in six domains (role 
physical, bodily pain, general health, vitality, social functioning and mental health). CH 
patients also scored significantly lower than migraineurs in the bodily pain and social 
functioning domains. Table 8 and Figure 1 show SF-36 scores of the respective groups; 
Table 9 summarizes the P values. After the termination of the cluster period, CH 
patients’ scores were higher in 7 of the 8 SF-36 domains (the exception being the 
physical functioning domain): this improvement was significant in the role physical, 
bodily pain and social functioning domains (P < 0.002). Vitality and mental health 
scores also tended to improve (P = 0.063 and P = 0.074, respectively). There was no 
statistical difference between CH patients outside the bout and headache-free controls 
(Figure 1). There was no correlation between SF-36 scores and the characteristics (age, 
disease duration, length of the present CH period and number of attacks) of CH patients, 
with the exception of a correlation between VT scores and age (r = 0.402, P = 0.0275) 
and MH with disease duration (r = 0.621, P = 0.0103). There was no significant 
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difference between the scores of sumatriptan users and non-users. Migraineurs scored 
lower than controls in all SF-36 domains; the differences were statistically significant 
for physical functioning, role physical, bodily pain, general health and social 
functioning scores. 
 
Table 8. Generic  HRQoL: SF-36 scores of CH patients, migraineurs and controls. PF: 
physical functioning, RP: role physical functioning, BP: bodily pain, GH: general health, VT: vitality, SF: 
social functioning, RE: role emotional functioning, MH: mental health  
 
SF-36 
domains 
Cluster headache Migraine Controls 
during the period after the period 
 Mean SD Mean SD Mean SD Mean SD 
PF 78.23 23.29 76.62 22.25 71.5 30.04 94.0 6.32 
RP 30.15 37.83 59.56 43.09 52.68 35.58 86.67 26.50 
BP 17.17 16.85 69.85 22.91 43.54 25.92 88.53 12.57 
GH 53.75 21.60 51.85 20.36 54.82 18.42 72.27 18.06 
VT 44.37 25.93 53.97 22.01 51.96 19.69 62.33 20.86 
SF 47.14 25.02 69.12 22.45 60.70 25.62 83.33 16.14 
RE 39.57 43.52 51.93 46.54 60.65 31.47 57.72 38.73 
MH 54.25 20.44 63.06 19.07 64.12 20.06 73.33 17.35 
 
Table 9. Generic HRQoL: p values (Kruskal-Wallis ANOVA and Dunn’s Multiple 
Comparisons Tests); ns: non significant (p>0.05). See Table 8 for abbreviations 
 
SF-36 
domains 
Kruskal-Wallis 
ANOVA 
CH period vs 
migraine 
CH period vs 
controls 
migraine vs 
controls 
PF 0.0329 ns ns <0.05 
RP <0.0001 ns <0.001 <0.05 
BP <0.0001 <0.001 <0.001 <0.01 
GH 0.0171 ns <0.05 <0.05 
VT 0.0454 ns <0.05 ns 
SF <0.0001 <0.05 <0.001 <0.05 
RE ns ns ns ns 
MH 0.0095 ns <0.01 ns 
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Figure 1. Generic HRQoL: graphical representation of the SF-36 scores in the 
respective groups 
 
Headache-specific HRQoL 
Patients during the CH period scored the lowest on all three MSQ 2.1 subscores. There 
was a significant difference between CH patients and controls as well as between 
migraineurs and controls (P < 0.001 on all subscores for both patient groups vs. 
controls). The difference between CH patients’ scores and those of migraineurs was not 
significant. After the bout, CH patients’ subscores improved dramatically and were 
similar to the headache-free control values (Figure 2). There was no correlation between 
MSQ2.1 scores and the characteristics (age, disease duration, length of the CH period, 
number of attacks, type of abortive drug) of CH patients. MSQ2.1 scores and P-values 
are presented in Table 10 and depicted in Figure 2. 
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Table 10. Headache-specific HRQoL in CH patients, migraineurs and controls: 
MSQ2.1 scores RR: Role-restrictive, RP: role-preventive, EF: emotional function. 
 
MSQ 2.1 
domains 
Cluster headache Migraine Controls 
during the period after the period 
 Mean SD Mean SD Mean SD Mean SD 
RR 39.64 20.39 92.16 10.74 46.92 15.31 97.26 5.18 
RP 52.19 26.33 95.97 10.12 67.37 17.27 99.2 2.77 
EF 50.96 25.44 94.84 13.52 75.43 14.58 99.19 2.21 
 
 
 
Figure 2. Headache-specific HRQoL: graphical representation of MSQ2.1 scores 
in the respective groups 
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Correlation between the SF-36 and MSQ2.1 questionnaires 
As expected, the bodily pain subscore of SF-36 correlated with all MSQ2.1 subscores: 
more severe pain was associated with more pronounced limitations in role and 
emotional functioning. Limitations in the role physical domain also correlated with loss 
of functioning in all MSQ2.1 subscores. Of the four SF-36 subscores reflecting physical 
health, role physical and bodily pain scores correlated with both the role [role function-
restrictive (RR), role function-preventive (RP)] and emotional (EF) components of 
MSQ2.1, while SF-36’s physical functioning score correlated with emotional 
functioning on MSQ2.1. The fourth, i.e. the general health score, showed no correlation. 
Of the four SF-36 subscores related to mental health (vitality, social functioning, role 
emotional and mental health) three (VT, SF and MH) positively correlated with 
emotional functioning, and two (VT and RE) with the role-function preventing aspect of 
CH. Surprisingly, there was no correlation between physical functioning and the role 
functioning items of MSQ2.1 or between the emotional functioning subscores of the 
two instruments (RE and EF). The correlation between the SF-36 and MSQ2.1 
subscores is presented in Table 8. 
 
Table 11. Correlation between SF-36 and MSQ2.1 subscores (Spearman Rank Order 
Correlations).  See Table 8 and 10 for abbreviations. 
 
 RR RP EF 
PF ns ns r=0,4635 p=0.0099 
RP r=0.4293 p=0.0159 r=0.4553 p=0.0101 r=0.4327 p=0.0169 
BP r=0.4933 p=0.0041 r=0.3983 p=0.024 r=0.4062 p=0.0234 
GH ns ns ns 
VT ns r=0.3691 p=0.0488 r=0.5042 p=0.0062 
SF ns ns r=0.3657 p=0.043 
RE ns r=0.4477 p=0.0149 ns 
MH ns ns r=0.4740 p=0.0108 
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5.2 Validation of the Comprehensive Headache-specific Quality of life 
Questionnaire  
 
5.2.1 Validation in migraineurs and tension type headache patients 
 
Observations about completing the questionnaire 
The questionnaires were administered to a total of 217 patients. On average, it took less 
than 20 minutes to complete both of the questionnaires. Filling in the questionnaire did 
not present any difficulty, as reported by the patients. The majority of the patients 
answered all questions. Of CHQQ’s 23 questions, 13 had no missing answers. Fifteen 
participants did not answer the question about the influence of their headaches on their 
sexual life. For the remaining nine questions, the rate of missing answers was very low 
(1 to 3 per question). All questions were completely answered by 202 patients (93% of 
the 217 patients). As Statistica excludes subjects with missing data from reliability and 
validity analyses, these were calculated taking the 202 patients into account. 
 
Patient characteristics 
Among the 202 patients we studied 169 were females and 33 were males. The mean age 
was 35.1 years, (SD 11.53; range 18–68). All patients were Caucasian. One hundred 
and forty-one patients were in paid employment (70%), 20 were students (10%), 10 
were on maternity leave (5%), 9 were retired (4.5%) and 3 unemployed (1.5%); 19 
preferred not to answer the question about employment status. One hundred and sixty-
eight patients (83.2%) were migraineurs and 34 patients (16.8%) had TTH (11 episodic 
and 23 chronic). Patients with chronic TTH had a significantly higher attack frequency 
(mean 33.5, SD 13.5 vs. mean 6.5, SD 4.0, p<0.001) and more headache days (mean 
27.7, SD 5.07 vs. mean 7.61, SD 4.33, p<0.001) but smaller minimum (mean 1.97, SD 
1.56 vs. mean 4.91, SD 6.19 hours, p¼0.027) and maximum (mean 9.4, SD 6.67 vs. 
mean 33.71, SD 24.0 hours, p<0.001) lengths of treated attack than patients with 
episodic TTH. The other headache characteristics were not significantly different in the 
chronic and episodic TTH groups. The male:female ratio was non-significantly higher 
in the chronic group (10 males and 13 females vs. 2 males and 9 females, p=0.252, 
Fisher’s exact test). Fifty-three patients (26.2%) also had a history of depression. Of 
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these, 42 were migraineurs and 11 TTH patients (4 episodic and 7 chronic). Depression 
occurred in 25% of the migraine group and 32% of the TTH group (p¼0.396, Fisher’s  
exact test). Data about the patient group are presented in Table 12. 
 
Table 12. Patient characteristics. Data are presented as mean±SD. All: All patients; M: 
Migraine group;
  
TTH: Tension-type headache group; IHS: International Headache Society; 
VAS: Visual analogue scale.  
 
 
 
Reliability 
The questionnaire demonstrated excellent reliability, with Cronbach’s alpha being 0.913 
for the whole sample, 0.892 in the subgroup of migraineurs and 0.928 in the subgroup 
of TTH patients. The physical, mental and social dimensions also showed good 
reliability in the whole population and also in the diagnostic subgroups (Table 13). 
 
 
Variable All M TTH 
p 
M vs TTH 
Age (year) 35.1±11.5 34.77±10.8 36.20±14.5 0.899 
Disease length 12.23±10.4 13.31±10.1 6.80±10.4 <0.001 
Minimum length of treated 
attack (hour) 
10.8±12.9 11.51±13.5 7.48±9.6 0.004 
Maximum length of treated 
attack (hour) 
41.15±31.7 45.72±32.6 19.91±14.2 <0.001 
Mean attack length (hour) 24.8±20.9 27.61±21.5 11±9.5 <0.001 
Headache severity 
(IHS rating scale) 
2.32±0.6 2,45±0.5 1.68±0.5 <0.001 
Headache severity (VAS) 67.52±21.1 72.13±18.0 46.94±20.9 <0.001 
Attack frequency last month 7.49±10.8 4.10±3.6 24.13±17.4 <0.001 
Number of days with 
headache last month 
8.59±8.2 6.14±4.6 20.54±11.3 <0.001 
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Table 13. The reliability of the questionnaire and its main dimensions: Cronbach’s 
alpha values. TTH: tension type headache 
 
 Migraine group TTH group Whole sample 
Whole 
questionnaire 
0.892 0.928 0.913 
Physical dimension 0.819 0.807 0.832 
Mental dimension 0.801 0.874 0.814 
Social dimension 0.814 0.846 0.829 
 
 
Validity 
Criterion validity 
In the whole sample, headache severity was negatively correlated with almost all items 
(22 items correlated significantly with the VAS and 21 with the IHS headache severity 
scale). Mean attack length and attack frequency showed significant negative 
correlations with 19 and 13 items, respectively. Age and length of disease were the 
clinical variables that showed significant correlations with the smallest amount of items 
(Table 14). The results were similar in the subgroup of migraineurs. In the TTH 
subgroup, headache severity (measured in both ways) and age were negatively 
correlated with six items each. Other clinical data showed significant correlations with a 
smaller number of items. In the whole sample, the physical dimension of the instrument 
was significantly correlated with all clinical characteristics. The mental dimension was 
significantly correlated with six of the nine clinical characteristics (the exceptions being 
attack frequency, headache days per month and maximum length of attacks). The social 
dimension was correlated with eight of the nine clinical characteristics; age did not 
show a significant correlation with this dimension. In the migraine subgroup most 
correlations were also significant. Neither dimension was correlated with the number of 
headache days per month, the mental dimension was not correlated with attack 
frequency and the maximum length of attacks, and the social dimension was not 
correlated with age. In the TTH group the questionnaire’s physical and social 
dimensions were negatively correlated with headache severity, whereas the mental 
dimension showed no significant correlation with the clinical characteristics. In the 
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whole sample the total score of the instrument correlated significantly with seven of the 
nine headache characteristics; there was no significant correlation with age and the 
number of headache days per month. In the subgroup of migraineurs the total score also 
showed significant correlations with most (7/9) clinical data, the exceptions being attack 
frequency and days with headache in the last month. There were no significant 
correlations between the clinical data and the total score in the subgroup of patients with 
TTH.   
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Table 14. Criterion validity: the correlations between the items, dimensions and total 
scores of the instrument with the clinical characteristics (Spearman Rank Order 
Correlations). For the sake of brevity only the whole group’s results are presented about the correlation 
of the individual items and headache characteristics. Marked correlations (bold and italic) are significant. 
(p<0.05).All: All patients,  M: Migraine subgroup,  T: Tension-type headache subgroup. 
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Convergent validity 
In the whole group, and also in the diagnostic subgroups (migraine and TTH), the 
majority of items relevant to physical functioning showed significant correlations with 
the physical domains of SF-36, especially with the bodily pain and role physical 
domains. The mental and social items of the instrument correlated with the four mental 
health domains of S0F-36, particularly with social functioning and mental health. The 
questions asking about general health perceptions and irritability correlated significantly 
with all eight domains of the SF-36, and six more items showed significant correlations 
with seven SF-36 domains (Table 15). The physical dimension of the new instrument 
showed significant correlations with all ‘physical’ domains of the SF-36 in the total 
sample and also in the M and TTH groups, except for the correlation with SF-36’s 
bodily pain domain in the TTH group. The mental dimension had significant 
correlations with all SF-36 domains, with the exception of the correlation with the role 
emotional domain in TTH patients. The social dimension had significant correlations 
with the majority of SF-36 domains, except for the role emotional SF-36 domain, which 
was significantly correlated with it only in the TTH group, and the physical functioning 
SF-36 domain, which was not significantly correlated with the social dimension in TTH 
sufferers. The total score of the instrument correlated significantly with all SF-36 
domains in the whole sample and in the migraine group; the total scores in the TTH 
group did not correlate with the social functioning domain of SF-36, but showed 
significant correlations with all other SF-36 domains. 
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Table 15. Convergent validity: the correlation of the questionnaire’s individual items, 
dimensions and total score with the SF-36 instrument (Spearman Rank Order 
Correlations). For the sake of brevity only the whole group’s results are presented about 
the correlation of the individual items and SF-36 domains. Marked correlations (bold 
and italic) are statistically significant (p<0.05).All: All patients,  M: Migraine group,  T: Tension-
type headache group, SF-36 domains: PF: physical functioning, RP: role physical, BP: bodily pain, GH: 
general health, VT: vitality, SF: social functioning, RE: role emotional, MH: mental health. 
 
  PF RP BP GH VT SF RE MH 
Work 
performance 
All 
0.085 0.371 0.601 0.117 0.005 0.239 -0.000 0.032 
Household chores All 0.086 0.305 0.455 0.090 0.012 0.186 -0.019 0.024 
Social life All 0.026 0.320 0.439 0.020 -0.005 0.195 -0.037 -0.016 
Leisure activities All 0.074 0.297 0.394 0.061 0.016 0.147 0.005 0.014 
Vacations/ 
awaydays 
All 
0.183 0.392 0.431 0.138 0.028 0.221 0.069 0.048 
Physical health All 0.204 0.416 0.495 0.101 0.065 0.221 0.030 -0.007 
Appearance All 0.023 0.292 0.406 0.036 0.053 0.264 0.063 0.030 
Intrafamiliar 
relations 
All 
0.150 0.337 0.384 0.188 0.206 0.345 0.097 0.201 
Sexual life All 0.108 0.328 0.367 0.046 0.021 0.160 0.048 0.006 
Sleep All 0.262 0.231 0.345 0.135 0.163 0.223 0.129 0.152 
Energy All 0.134 0.222 0.306 0.109 0.104 0.116 0.125 0.131 
Mood All 0.116 0.080 0.222 0.105 0.171 0.130 0.069 0.246 
Memory All 0.277 0.045 0.155 0.267 0.254 0.289 0.251 0.298 
Concentration All 0.289 0.128 0.171 0.300 0.187 0.310 0.254 0.238 
Thinking All 0.095 0.213 0.299 0.192 0.219 0.332 0.149 0.288 
General health 
perceptions 
All 
0.279 0.358 0.262 0.400 0.214 0.268 0.254 0.256 
Irritability All 0.170 0.209 0.283 0.183 0.230 0.344 0.205 0.246 
Frustration All 0.128 0.128 0.205 0.223 0.220 0.301 0.202 0.308 
Abortive 
medication use 
All 
0.153 0.168 0.233 0.036 -0.026 0.235 0.038 -0.008 
Financial 
situation 
All 
0.185 0.203 0.289 0.034 0.026 0.197 -0.007 -0.010 
Embarrassment 
due to headaches 
All 
0.073 0.254 0.141 0.074 0.023 0.127 0.136 0.067 
Worries about 
headaches 
All 
0.148 0.181 0.326 0.221 0.102 0.299 0.129 0.197 
Life enjoyment All 0.212 0.195 0.195 0.334 0.354 0.336 0.109 0.350 
Physical 
score 
All 0.252 0.419 0.503 0.186 0.117 0.318 0.109 0.142 
M 0.270 0.343 0.487 0.204 0.142 0.346 0.131 0.185 
T 0.428 0.454 0.338 0.437 0.460 0.245 0.374 0.440 
Mental 
score 
All 0.263 0.318 0.384 0.378 0.254 0.436 0.256 0.351 
M 0.252 0.249 0.335 0.378 0.267 0.411 0.254 0.373 
T 0.492 0.593 0.545 0.676 0.567 0.536 0.378 0.589 
Social score All 0.221 0.414 0.500 0.219 0.234 0.392 0.101 0.204 
M 0.233 0.291 0.431 0.200 0.268 0.405 0.098 0.245 
T 0.321 0.649 0.580 0.637 0.575 0.416 0.420 0.523 
Total score All 0.270 0.413 0.525 0.291 0.203 0.443 0.188 0.264 
M 0.274 0.338 0.478 0.295 0.235 0.429 0.179 0.304 
T 0.498 0.645 0.553 0.778 0.591 0.458 0.486 0,512 
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Discriminative validity 
When comparing the results of the two diagnostic groups (M and TTH), we found that 
patients suffering from TTH had higher scores (better QOL) at each item. The 
difference was significant for 16 of the 23 items (8/8 items of the physical dimension, 
4/5 items of the social dimension and 3/10 items of mental dimension) (Table 16). The 
differences between M and TTH on CHQQ’s three dimensions and total score were also 
highly significant (p<0.004); again, TTH sufferers had higher scores (better QOL). 
Within the TTH group, there was no significant difference in the CHQQ scores (items, 
dimensions and total score) of episodic and chronic patients, apart from work 
performance (p¼0.014) and physical health (p¼0.016), which were more severely 
affected in chronic TTH. 
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Table 16.  Discriminative validity. Item, dimension and total scores (mean±SD) of the 
migraine group versus the tension-type headache group. Marked differences (bold and 
italic) are significant (p<0.05, Mann-Whitney tests). Higher scores reflect a better QOL. 
M: migraine group, TTH: tension type headache group.  
 
 
 
Mean±SD 
M 
Mean±SD 
TTH 
p level 
Work performance 32.74±25.5 51.47±24.26 <0.001 
Household chores 31.85±25.74 54.41±26.83 <0.001 
Social life 29.17±27.4 52.21±30.5 <0.001 
Leisure activities 27.98±25 53.68±27.24 <0.001 
Vacations/awaydays 43.30±35.56 69.12±32.89 <0.001 
Physical health 30.06±26.82 58.09±29.25 <0.001 
Appearance 40.62±24.81 61.03±25.24 <0.001 
Relationship with  
other family members 
42.11±24.83 58.82±27.67 <0.001 
Sexual life 35.57±33.20 61.03±32.61 <0.001 
Sleep 38.8±29.23 50.74±29.16 0.030 
Energy 31.99±19.3 42.65±20.11 0.002 
Mood 28.57±19.86 36.03±22.41 0.080 
Memory 65.48±30.39 73.53±25.68 0.177 
Concentration 37.65±26.1 55.15±24.39 <0.001 
Thinking 43.75±25.53 62.5±26.58 <0.001 
General health 
 perceptions 
54.46±26.86 70.59±27.5 0.001 
Irritability 44.20±32.19 52.21±35.59 0.252 
Frustration 39.43±28.11 44.85±26.44 0.298 
Abortive medication use 22.62±27.6 44.85±40.34 0.005 
Financial situation 68.01±28.51 77.21±29.56 0.039 
Embarrassment  
due to headaches 
82.44±27.39 89.71±23.09 0.073 
Worries about headaches 39.14±25.98 47.79±30.5 0.170 
Life enjoyment 44.94±30.81 54.41±25.35 0.052 
Physical dimension 35.84±19.29 56.53±18.76 <0.001 
Mental dimension 45.77±17.75 55.88±17.39 0.004 
Social dimension 42.11±22.01 62.21±21.27 <0.001 
Total score 41.52±17.24 57.48±16.87 <0.001 
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Dimension structure of the questionnaire 
In order to examine whether the individual items were mathematically related to the 
hypothesized dimensions of the instrument, we performed an analysis of item– 
dimension correlations on the sample. Spearman’s rank order correlations were 
significant for all items and all dimensions. With the exception of the Energy item 
(which showed the highest correlation with the Physical dimension), all the items 
showed the highest correlation with their intended dimensions (Table 17).  
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Table 17. Item–dimension correlations (Spearman Rank Order Correlations) on the 
sample. All correlations are significant (p <0,05).  
 
 Physical Mental Social Total 
Highest 
correlation is 
with relevant 
dimension 
Physical dimension      
Work performance 0,757728 0,458167 0,700616 0,726158 + 
Household chores 0,710302 0,350793 0,664333 0,639927 + 
Physical health 0,751094 0,449268 0,694886 0,715548 + 
Appearance 0,724138 0,408714 0,575937 0,645952 + 
Sexual life 0,737800 0,399855 0,635344 0,660815 + 
Sleep 0,577862 0,371600 0,424831 0,515695 + 
General health 
 perceptions 
0,582935 0,501696 0,416129 0,571881 + 
Abortive medication use 0,465216 0,313194 0,345622 0,427700 + 
Social dimension      
Social life 0,709962 0,320357 0,810299 0,670466 + 
Leisure activities 0,690247 0,323934 0,786617 0,655385 + 
Vacations/awaydays 0,663661 0,351846 0,801158 0,662569 + 
Relationship with  
other family members 
0,599443 0,561760 0,679819 0,681815 + 
Financial situation 0,471571 0,419525 0,609110 0,543625 + 
Mental dimension      
Energy 0,549684 0,476992 0,408685 0,537868 - 
Mood 0,455913 0,548833 0,328400 0,505074 + 
Memory 0,331657 0,620747 0,298023 0,483458 + 
Concentration 0,493701 0,607196 0,444419 0,589018 + 
Thinking 0,543115 0,710080 0,460009 0,666515 + 
Irritability 0,297053 0,653614 0,285495 0,481545 + 
Frustration 0,291822 0,690378 0,251766 0,483403 + 
Embarrassment  
due to headaches 
0,237955 0,427475 0,235983 0,348968 + 
Worries about headaches 0,366430 0,684187 0,375621 0,555774 + 
Life enjoyment 0,359789 0,624671 0,307846 0,505788 + 
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Observations of the SF-36 measure 
In order to compare the performance of the new questionnaire and the SF-36, we 
calculated the correlations between the SF-36 domains and the clinical characteristics. 
In general, significant correlations were rare and of low to moderate strength. In the 
whole sample attack frequency was negatively correlated with role physical, vitality, 
role emotional and mental health domains, and headache severity was negatively 
correlated with the role physical and bodily pain domains. In the migraine group attack 
frequency was not correlated with any SF-36 domain, and headache severity was 
negatively correlated with the role physical and bodily pain domains. In the TTH group 
attack frequency was negatively correlated with the role physical and bodily pain 
domains, and headache severity with the bodily pain domain (these data are not shown 
in the tables). We also assessed the discriminative validity of the SF-36 measure in the 
two groups. Patients suffering from TTH had significantly higher scores (reflecting 
better QOL) in two of the eight dimensions (role physical and bodily pain), whereas 
migraineurs had numerically higher scores in six domains, the difference being 
significant only in two, vitality and mental health (Table 18). 
 
Table 18. Discriminative validity of the SF-36 questionnaire. SF-36 scores of the 
migraine and TTH groups (mean±SD). Marked differences (bold and italic) are 
significant (p<0.05, Mann-Whitney tests). M: migraine group, TTH: tension-type headache 
group. SF-36 domains: PF: physical functioning, RP: role physical, BP: bodily pain, GH: general health, 
VT: vitality, SF: social functioning, RE: role emotional, MH: mental health. 
 
SF-36 domain M TTH p 
PF 78.94±27.78 76.89±29.07 0.383 
RP 32.12±45.43 61.49±43.54 <0.001 
BP 29.83±20.24 40.95±20.51 0.002 
GH 59.34±22.23 54.31±18.51 0.091 
VT 54.97±20.93 47.16±20.09 0.030 
SF 63.33±23.55 62.50±21.13 0.895 
RE 65.19±46.28 50.40±44.14 0.052 
MH 64.87±20.64 54.81±19.16 0.004 
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5.2.2. Validation in medication overuse headache   
 
The reliability of the questionnaire was adequate (Cronbach alpha = 0,869 for the whole 
questionnaire, and 0.679 to 0.759 for its dimensions) in this group of MOH patients 
(Table 19).  
 
Table 19. The reliability of the questionnaire and its main dimensions in medication 
overuse headache patients: Cronbach’s alpha values. 
 
Physical dimension 0.700 
Mental dimension 0.759 
Social dimension 0.679 
Total score 0.869 
 
 
When examining the criterion validity of the instrument, we found negative correlations 
between the clinical data and CHQQ scores of the patients, as we had expected. 
Significant, mild to moderate correlations were observed between headache severity 
(measured both with a visual analogue scale and the IHS scale) and the questionnaire’s 
social dimension and total score. The questionnaire’s dimensions and total score were 
not significantly correlated with the other clinical data. In order to compare the two 
QOL questionnaires’ performance, we also examined the criterion validity of the SF-36 
in this sample. We found significant, but weak negative correlations between headache 
severity (measured both by VAS and IHS scales) and SF-36’s bodily pain dimension. 
The patients’ age, headache and attack frequency showed mild, but significant negative 
correlations with SF-36’s physical functioning domain. Surprisingly, we found 
significant positive correlations between disease duration and 4 of the 8 SF-36 domains 
(bodily pain, vitality, social functioning, and mental health) (Table 20).   
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Table 20. Criterion validity of the CHQQ and SF-36 questionnaires in medication 
overuse headache patients (Spearman Rank Order Correlations). Marked differences 
(bold and italic) are significant (p<0.05). CHQQ: Comprehensive Headache-related QOL 
Questionnaire VAS: Visual analogue scale. SF-36 domains: PF: physical functioning, RP: role physical, 
BP: bodily pain, GH: general health, VT: vitality, SF: social functioning, RE: role emotional, MH: mental 
health. 
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CHQQ 
Physical 
 
-0,199 
 
0,077 
 
0,123 
 
0,124 
 
-0,171 
 
-0,227 
 
-0,208 
 
-0,239 
 
-0,244 
CHQQ 
Mental 
 
-0,067 
 
0,236 
 
0,009 
 
0,027 
 
-0,140 
 
-0,235 
 
-0,134 
 
-0,180 
 
-0,193 
CHQQ 
Social 
 
-0,238 
 
-0,031 
 
0,130 
 
0,166 
 
-0,090 
 
-0,158 
 
-0,234 
 
-0,257 
 
-0,330 
CHQQ 
Total 
 
-0,205 
 
0,088 
 
0,101 
 
0,118 
 
-0,172 
 
-0,252 
 
-0,220 
 
-0,287 
 
-0,290 
PF -0,408 0,081 -0,360 -0,354 -0,211 -0,327 -0,060 -0,095 0,163 
RP -0,222 0,194 -0,104 -0,082 -0,080 -0,250 -0,205 -0,158 -0,059 
BP 0,079 0,343 0,151 0,176 0,009 -0,401 -0,205 -0,382 -0,358 
GH -0,301 0,118 -0,057 -0,025 -0,238 -0,219 -0,164 -0,111 0,060 
VT 0,084 0,322 -0,041 -0,048 -0,038 -0,254 -0,117 0,044 0,034 
SF -0,139 0,381 -0,040 -0,085 0,044 -0,113 0,058 -0,121 -0,071 
RE -0,297 0,207 -0,245 -0,288 -0,146 -0,165 0,038 0,049 0,251 
MH -0,097 0,317 -0,145 -0,171 -0,100 -0,278 0,048 0,001 0,055 
 
 
During the examination of convergent validity the dimensions of the questionnaire 
showed positive and almost always significant correlations with the SF-36 domains. 
The physical dimension was significantly correlated to all SF-36 domains except for 
vitality. The mental dimension was significantly correlated to all SF-36 domains except 
for the role physical domain. The social dimension was significantly correlated to 5 of 
the 8 SF-36 domains (physical functioning, role physical, bodily pain, general health 
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and social functioning). Most of the significant correlations of the CHQQ’s dimensions 
and SF-36 domains were mild to moderate. The total score of the questionnaire showed 
significant, mostly mild to moderate correlations with all SF-36 domains; it was 
strongly correlated to the bodily pain domain of the SF-36 (Table 21).  
 
Table 21. Convergent validity of the CHQQ in medication overuse headache patients: 
the correlation of the questionnaire’s dimensions and total score with the SF-36 
instrument (Spearman Rank Order Correlations). Marked differences (bold and italic) 
are significant (p<0.05). CHQQ: Comprehensive Headache-related QOL Questionnaire SF-36 
domains: PF: physical functioning, RP: role physical, BP: bodily pain, GH: general health, VT: vitality, 
SF: social functioning, RE: role emotional, MH: mental health. 
 
CHQQ PF 
 
RP 
 
BP 
 
GH 
 
VT 
 
SF 
 
RE 
 
MH 
 
Physical 
0,4707 0,325 0,538 0,411 0,1625 0,543 0,328 0,411 
Mental 
0,356 0,246 0,581 0,418 0,560 0,474 0,342 0,609 
Social 
0,377 0,454 0,556 0,311 0,131 0,498 0,166 0,256 
Total 
0,461 0,396 0,637 0,450 0,361 0,576 0,328 0,522 
 
 
During the examination of discriminative validity we compared the QOL of MOH 
patients and chronic tension type headache patients. All dimensions scores and the total 
score were lower in MOH patients than in CTTH patients; the difference was significant 
except for the mental dimension (p=0,055). SF-36 scores of MOH patients were also 
lower, the difference was not significant in three of the four SF-36 mental domains (SF, 
RE, MH) (Table 22). 
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Table 22. Discriminative validity of the questionnaire and its main dimensions in 
medication overuse headache patients and chronic tension type headache. Marked 
correlations (bold and italic) are significant (p<0.05, Mann-Whitney tests). MOH: 
medication overuse headache, CTTH: chronic tension type headache  
 
 
MOH CTTH p value 
Physical dimension 36,9 52,6 0,0002 
Mental dimension 42,9 51,0 0,0545 
Social dimension 41,8 56,6 0,0053 
Total score 40,6 52,8 0,0009 
 
 
5.2.3 Examination of responsivity in medication overuse headache  
 
Baseline CHQQ values and comparison to episodic migraine patients 
The headache-specific quality of life of MOH patients, as measured by the CHQQ 
instrument, was low as regards the physical, mental and social dimensions as well as the 
total score. With the exception of the physical dimension the values were numerically 
lower than those of episodic migraine (EM) patients; the difference was statistically 
significant only for the mental dimension of the CHQQ (Table 23). There was no 
difference between the baseline CHQQ values of the in-, and outpatient groups (Table 
24).  
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Table 23. The quality of life of medication overuse headache (MOH) patients compared 
to patients suffering from episodic migraine (EM). Data are presented as mean ± SD. 
With the exception of the physical domain, MOH patients had lower values; the 
difference was significant only for the mental domain (Mann-Whitney tests). CHQQ: 
Comprehensive Headache-related QOL Questionnaire MOH: medication overuse headache, EM: episodic 
migraine. 
 
 CHQQ scores 
 Physical Mental Social Total 
MOH  41,6 ± 8,7 39,3 ± 8,9 41,5 ± 9,5 40,6 ± 5,5 
EM  39,2 ± 17,3 47,6 ± 15,4 45,6 ± 19,9 44,2 ± 14,4 
p value 0,3252 0,0315 0,3930 0,2593 
 
 
Table 24. The baseline quality of life of MOH patients in the in-, and outpatient groups. 
Data are presented as mean ± SD. There were no significant differences between the 
groups (Mann-Whitney tests). CHQQ: Comprehensive Headache-related QOL Questionnaire 
 
 CHQQ scores 
 Physical Mental Social Total 
Inpatients  38,8 ± 10,2 39,3 ± 8,3 40 ± 11,9 39,3 ± 4,4 
Outpatients 44,1 ± 7,1 39,4 ± 10,1 42,9 ± 7,5 41,8 ± 6,4 
p value 0,4150 0,9072 0,5586 0,3837 
 
 
Improvement of the clinical characteristics and quality of life 
The clinical characteristics of the patients’ headaches and their quality of life before and 
after the treatment period are summarized in Table 25. After the treatment period the 
clinical characteristics of patients’ headaches improved significantly. In particular, the 
mean number of headache days and of attacks decreased by almost 50%. A meaningful 
effect (defined as a 50% or greater decrease of headache frequency or attack frequency) 
was seen in five patients. The quality of life also improved. All the individual items of 
the CHQQ questionnaire showed higher values (better quality of life) after treatment, 
which was significant in 17 of the 23 items (Figure 3). The dimensions and total score 
of CHQQ also showed a significant increase after the treatment period; an increase of at 
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least 50% of the CHQQ total score was observed in seven patients. In four of these 
seven patients a meaningful decrease of headache and attack frequency was also 
observed. The dimensions and total score of the CHQQ showed remarkably uniform 
changes in all patients (Figure 4). 
 
Table 25. The headache characteristics and quality of life before and after the treatment 
period. Data are presented as mean ± SD. Significant improvement was seen in all 
clinical variables as well as the CHQQ dimensions and total score. The p values reflect 
the results of Wilcoxon tests. VAS: visual analogue scale, IHS: International Headache Society, 
CHQQ: Comprehensive Headache-related QOL Questionnaire  
 
  Baseline Post-
treatment 
p value 
H
ea
d
ac
h
e 
ch
ar
ac
te
ri
st
ic
s Number of headache days per month 24,3 ± 5,7 13,5 ± 8,7 0,0025 
Number of attacks per month 23,7 ± 5,9 12,7 ± 9,2 0,0025 
Headache severity (VAS) 66,2 ± 13,5 41,2 ± 20,9 0,0025 
Headache severity (IHS) 2,1 ± 0,28 1,78 ± 0,38 0,0112 
Duration of attacks (hours) 9,9 ± 4,6 7,3 ± 4,4 0,0023 
Analgesic dose per month 36,2 ± 32,6 12,2  ± 8,9 0,0002 
Q
u
al
it
y
 o
f 
li
fe
 CHQQ Physical dimension 41,6 ± 8,7 63,7 ± 20,5 0,0021 
CHQQ Mental dimension 39,3 ± 8,9 57,8 ± 18,6 0,0041 
CHQQ Social dimension 41,5 ± 9,5 67,7 ± 18,1 0,0011 
CHQQ Total score 40,6 ± 5,5 62 ± 18,2 0.0011 
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Figure 3. Baseline and post-treatment means of individual CHQQ items. The asterisks 
mark the items where the improvement was statistically significant (*= p<0.05; 
**=p<0.01). CHQQ: Comprehensive Headache-related QOL Questionnaire  
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Figure 4. Individual baseline and post-treatment CHQQ results: dimensions and total 
score. Higher values represent better QOL. CHQQ: Comprehensive Headache-related QOL 
Questionnaire 
 
 
Correlations between the changes of clinical and QOL data 
As the data in Table 25 show, the significant improvement of the clinical outcome 
variables was parallelled by a significant improvement of headache-specific QOL. Most 
of the correlations between the change in clinical characteristics and that of CHQQ’s 
dimensions and total score were mild to moderate (Spearman’s r 0,2-0,4 and 0,4-0,6 
respectively) (Table 26). With the exception of the correlations between the 
improvement of headache severity (VAS) and the improvement of the total CHQQ 
score, the correlations were not significant.  
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Table 26. Correlation between the improvement of the patients’ headache 
characteristics and quality of life (dimensions and total score). Most correlations were 
mild to moderate (Spearman Rank Order Correlations). Marked differences (bold and 
italic) are significant (p<0.05). Significant correlation was only found between the 
improvement of headache severity (VAS) and the increase in CHQQ’s total score 
(p=0,037).  VAS: visual analogue scale, IHS: International Headache Society, CHQQ: Comprehensive 
Headache-related QOL Questionnaire  
 
 CHQQ 
 Physical Mental Social Total 
Number of headache days per month 0,176 0,108 0,075 0,152 
Number of attacks per month 0,179 0,101 0,072 0,149 
Duration of attacks (hours) 0,178 0,190 0,097 0,135 
Headache severity (VAS) 0,307 0,459 0,217 0,541 
Headache severity (IHS) 0,002 0,122 0,216 0,134 
Analgesic dose per month 0,419 0,132 0,327 0,327 
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6. Discussion 
 
6.1 Examination of health-related and condition-specific quality of life in episodic 
cluster headache  
 
In our study, generic and headache-specific HRQoL were found to be seriously 
impaired during the cluster period. This impairment was at least as severe as in 
migraineurs for most HRQoL domains; bodily pain and social functioning were 
significantly worse in CH. Using generic HRQoL measures for the comparison of 
different groups have the inherent disadvantage of not clarifying whether the results are 
caused by the index condition (at present, headache) or by concomitant illness. We tried 
to correct the possible bias by selecting control populations with a similar concomitant 
disease profile. Other possibilities would be either the careful elimination of all patients 
with any concomitant illness, or the study of large numbers of patients selected from the 
general population. Due to the small prevalence of CH none of these seemed feasible.   
 
Before this study, there was only a limited amount of data concerning overall quality of 
life in CH. One study used the MOS 20-Item Short Form Health Survey (SF-20) to 
assess the QOL and well-being of 208 consecutive patients in a headache clinic (38). 
Thirteen CH sufferers were included; other diagnoses were migraine, tension-type 
headache and ‘mixed headache’. CH patients had significantly worse pain scores and 
greater limitation in social functioning than migraine patients. Physical functions and 
general health perception of CH patients, however, were not different from those of 
other headache patients. The latter finding was in contrast with our observations of 
impaired general health during the cluster period. Due to the difference between the two 
generic HRQoL instruments the interpretation of the differences between the two 
studies was somewhat difficult. As the number of CH patients in the SF-20 study was 
small (only 10 to 12 CH patients were included when calculating the above-mentioned 
health scale scores)  and part of them were examined outside the bout (34), the 
generalizability of their results seemed doubtful. 
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D’Amico et al. administered the SF-36 to 56 Italian CH patients (34 episodic and 22 
chronic) during the active periods and compared the results with Italian normative data 
(34). Cluster headache was associated with a significant decrease (P < 0.0001) in six of 
the eight scales (role physical, bodily pain, general health, social functioning, role 
emotional and mental health). It is of interest that in our study five of these scales (role 
physical, bodily pain, general health, social functioning and mental health) were also 
significantly worse. There was no significant difference between the HRQoL of 
episodic and chronic CH patients. Surprisingly (but in accordance with our results), the 
comparison of sumatriptan users and those using a different abortive drug did not show 
any significant difference. Episodic patients were studied only in the active phase and 
mention was not made of any concomitant disease the patients may have had. 
Notwithstanding these limitations, there was a striking similarity between the SF-36 
profiles of Italian and Hungarian CH patients during the episode: five of the eight scales 
decreased in both populations, while physical functioning was not statistically different 
from controls. Italian CH patients had worse emotional role functioning than controls 
whereas Hungarian patients scored lower on the vitality subscore. On the whole, these 
data indicate that the HRQoL impairment in CH may be quite uniform in different 
cultural and linguistic contexts. 
 
The generic instrument SF-36 makes it possible to compare HRQoL in different 
medical conditions. Based on literature searches, our CH patients seemed to have a 
very unfavourable profile. All SF-36 subscores of the present CH population were 
significantly lower than those of patients with previous myocardial infarction (73). CH 
patients had significantly worse scores in all SF-36 dimensions except physical 
functioning than patients who had survived peritonitis (74). CH patients had more 
severe bodily pain, lower vitality, worse social functioning and mental health than 
patients with surgically treated hip arthrosis (75, 76), peripheral artery disease (76), or 
coronary artery disease (76). The comparison of SF-36 scores obtained in different 
languages and cultures is to be made with caution (77, 78). Nevertheless, as the similar 
profiles of Italian (34) and Hungarian CH sufferers indicated that the consequences of 
CH may be similar in other countries, too, the comparisons made above between the 
effects of CH and other medical conditions on HRQoL are not entirely unjustified. 
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MSQ2.1 has been widely used to study migraine-specific quality of life (79, 80). 
Results of a multinational investigation of HRQoL in migraineurs suggest that while 
migraine does interfere with quality of life, MSQ2.1 scores are also dependent on the 
socio-cultural setting (78). In our study, migraineurs’ role-function restrictive scores 
were comparable to values obtained in Australia and Canada, while role-function 
preventive and emotional functioning scores resembled Italian and Swedish values (78). 
MSQ2.1 was found to be more sensitive in detecting HRQoL changes of migraineurs 
than SF-36 (81). The same was observed when comparing scores of the present CH 
population during and after the bout. Due to its sensitivity, relative brevity and 
simplicity, MSQ2.1 may be useful as a measure of therapeutic efficacy in CH drug 
trials. 
 
Most of the items of SF-36 and all items of MSQ 2.1 concern the limitations in the 4 
weeks preceding the completion of the instrument. The similar time window allows for 
a comparison between the two instruments and also lets us appreciate the impact of the 
condition in a more precise way. In the present CH population the two instruments 
showed good correlation. It was surprising that limitations caused by CH were not 
significantly more severe than those of migraineurs, as would have been expected from 
personal accounts of patients (not included in this study) who suffer from both headache 
types. 
 
Being a generic HRQoL measure, SF-36 may not be sensitive enough to certain effects 
of CH on the patients’ functionality and well-being. The relative insensitivity of MSQ 
to the consequences of CH may be explained by the item selection process during the 
development of MSQ, which aimed at achieving a highly migraine-specific measure 
(79). We felt that these two instruments may not capture some essential aspects of CH. 
A simple example for the different effects of CH and migraine on QOL, not measured 
by SF-36 or MSQ, could be the way these headaches influence the quality of sleep. 
Differences in item selection and concept definition may also explain why subscales 
measuring seemingly related concepts (e.g. SF-36’s role emotional subscale and the 
emotional functioning subscale of MSQ2.1) do not correlate. That the partial lack of 
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correlation between the two instruments was not caused solely by the difference 
between CH and migraine was underlined by the finding of only low to modest 
correlation (r < 0.4) between MSQ2.1 and SF-36’s physical and mental composite 
scores in a large sample of migraineurs (79). 
 
This study, as well as the previous studies about quality of life in CH, may be criticised 
for the method of patient selection. Although CH is a severe condition that prompts 
medical consultation in most cases (82), patients with more severe limitations may be 
more motivated to seek medical advice in a specialized headache center. It is therefore 
possible that the self-perceived health limitations of our CH sample were more severe 
than those of an ‘average’ CH sufferer. A population-based approach may yield more 
precise results. In spite of these limitations, our study further demonstrated that CH can 
severely affect the sufferer’s functioning and well-being during the active period. The 
limitations seem to be at least as severe as those caused by migraine and are probably 
more severe than in a number of important conditions. 
 
As far as the effect of CH is concerned, two later studies are worth mentioning, 
although these did not measure HRQoL. A multicentric prospective German study 
assessed the effect of CH, examining patients with chronic CH (n=27), episodic CH in 
the active phase (n=26), episodic CH outside the active period (n=22), migraine patients 
(n=24) and healthy controls (n=31). Measurement tools included the German version of 
the Headache Disability Inventory (HDI), a 25-item questionnaire that calculates a total 
score as well as Emotion and Function domains, and a screening tool for psychiatric 
complaints. Quality of life was not formally assessed. Patients with active CH (chronic 
CH or episodic CH in the active phase) had significantly higher disability than 
migraineurs. Interestingly, CH patients outside of the bout had disability levels 
comparable to migraineurs, and significantly worse than controls. A higher number of 
attacks in the active CH groups was significantly correlated with higher disability 
(Emotion domain and total score). Although quality of life and disability are different 
(partially overlapping) concepts, the German study underlines that CH (in the active 
phase) severely affects the patients’ everyday life (83). 
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A Danish study investigated the socioeconomic burden of cluster headache in patients 
from a tertiary headache center. In total, 85 patients were included in the study, of these 
59 patients had episodic cluster headache (79%) and 16 patients chronic headache 
(21%). A specific questionnaire about quality of life was not included in the study. 
Lifestyle changes (mostly sleeping habits and avoidance of alcohol) were observed in 
96% of the patients. Daily living was restricted in 66 patients (79%),  and 11 patients 
(13%) had inhibition also outside the cluster period. 82% of the employed patients 
reported decreased work ability during cluster periods, one-third of the patients felt that 
cluster headache had limited their career. Work absence was higher in CH patients than 
among the general population. The use of medical services (specialists, off-hour 
services) and non-medical treatments was also significantly higher in these patients than 
among the general population (84). 
 
 
6.2 Validation of the Comprehensive Headache-specific Quality of life      
Questionnaire  
 
6.2.1 Validation in migraineurs and tension type headache patients 
 
We evaluated the psychometric properties of the Comprehensive Headache-related 
QOL Questionnaire in patients suffering from migraine or TTH headache. The 
questionnaire was easy to administer. The internal consistency of the questionnaire was 
excellent in the whole sample and also in the diagnostic subgroups. Tests of criterion 
and convergent validity were also adequate. The questionnaire was able to detect 
significant differences between the impact of two different headache types (migraine 
and TTH). The dimension structure of the instrument was confirmed. Thus, CHQQ 
seems to be a reliable and valid means of measuring the impact of headache on the 
individual’s QOL. The study population consisted of patients with episodic migraine 
and TTH. Patients with episodic and chronic TTH had very similar clinical 
characteristics (apart from attack frequency and number of days with headache) and 
similar QOL profiles (no significant differences were found in 21/23 items, 3/3 
dimensions and the total score), and therefore were treated as a single group. The reason 
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for this similarity may be the fact that patients were recruited at a tertiary center and 
patients with infrequent TTH or those whose headache did not cause a certain amount of 
impairment were not referred to this center for evaluation. 
 
The study population would have been larger if patients with probable migraine and 
probable TTH had also been included. We decided not to include these patients to avoid 
diagnostic errors, as the IHS classification foresaw a diagnostic overlap between these 
two headache types. We also aimed to define clearly distinguishable diagnostic groups 
because we felt that the assessment of discriminative validity could have been 
compromised by including the respective ‘probable’ cases.  
 
The length and ease of use of a questionnaire are important aspects of its usability (14) 
and questionnaire length can have a threshold effect on response rate (15). In our study 
the questionnaire did not present any difficulty for the patients and 93% filled in all 
questions. The question about the effect of headache on sex life was the most frequently 
unanswered one (7% of the patients), much lower than the 17% missing answers for a 
similar question in a French QOL study (61). The other questions were answered by 
more than 98% of the participants; equally high answer rates had been observed in 
previous studies of QOL in headache (52, 61). The high response rate indicated that the 
length of this questionnaire would probably not be a significant limiting aspect of its 
clinical use. This notion was confirmed in our later studies. While shorter QOL 
instruments can clearly have an important role in everyday practice (92), longer 
instruments such as the CHQQ may present a more detailed QOL profile, which could 
be especially useful in the areas of clinical and pharmacoeconomic research and/or 
healthcare planning. 
 
The reliability of an instrument can be assessed by different methods. Test–retest 
analysis, ie. the repeated application of an instrument to the same study population is 
the most commonly used alternative to measuring internal consistency. Test–retest 
analysis usually requires a 4-week gap between the two sessions, and therefore was not 
applied in this study. (This method would have been ethically incorrect, because the 
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majority of our patients clearly needed a change in their acute medications, and a 
significant portion also needed prophylactic therapy). 
 
If an instrument is developed for use in a clinical setting (ie. for following up individual 
patients), rather than for the comparison of groups in experimental circumstances, a 
high level of internal consistency (ie. an alpha exceeding 0.9) is the minimum 
requirement (19). In this respect CHQQ seemed to be adequate for use as a follow-up 
tool in individual patients, but we underline that formal clinical testing should precede 
its use for this purpose. On the other hand, CHQQ’s reliability was comparable to that 
of MSQ2.1 and quite noticeably better than the reliability of the MSQ, the dimensions 
of which had internal consistency values between 0.70 and 0.85 (51). 
 
A QOL instrument is required to demonstrate content validity, criterion and construct 
validity (20). Content validity expresses the degree to which the underlying construct 
(QOL) is comprehensively sampled by the instrument’s items (93). As already 
mentioned, the items included in the final version were the ones that were meaningful 
both for the patients and the clinicians involved, which is an aspect of content validity. 
The small number of missing responses may also reflect that the patients felt the 
questions covered important aspects of their condition. It is therefore reasonable to 
suggest that the instrument’s content validity was adequate. 
 
The instrument’s validity was formally assessed by measuring its criterion, convergent 
and discriminative validity. By assessing criterion validity in this study, most QOL 
instruments had low to moderate correlations with the clinical data. During the 
validation of the MSQ2.1 measure, self-reported frequency and severity of headaches, 
duration of the attacks, and the time since the last severe headache were used to test 
for criterion validity (51). These showed significant but moderate correlations with the 
MSQ2.1 dimensions and total score. The validation study of the MQoLQ- 24 (53), an 
instrument designed for assessing the acute changes in QOL during a migraine attack, 
found that most correlations between the instrument’s domains and clinical data were 
moderate: the strongest correlations were between the work domain of the instrument 
and limitation of activity (r=0.30 to r=0.51); the weakest correlations were seen with the 
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concerns/feeling domain, but even there, the strongest correlation was with activity 
limitation (r=0.19 to r=0.41). In the validation study of the French QVM instrument, the 
frequency, severity, and treatment resistance of headaches, as well as headache-related 
disability, were significantly correlated with QVM’s total score and subscales; 
correlation coefficients were not reported (54). During the validation study of the 
MSQOL correlations with clinical variables were not calculated; instead, groups were 
created according to the severity of clinical symptoms and ANOVAs of MSQOL scores 
calculated: increased disease severity was associated with worse QOL (52). In this study 
more severe external measures of headache were related to a worse QOL. The strength 
of the correlations we observed (weak to moderate) was comparable to those found in 
the above-mentioned studies. The strength of correlations, and the fact that the items, 
dimensions and total score of the instrument did not correlate significantly with all 
clinical data, are not surprising: the symptoms of a disease do not invariably correlate 
with QOL scores (94). This is partly explained by the fact that the items in a QOL 
instrument can be divided into two main types: causal indicators and effect indicators. 
Studies of the relationship between symptoms and QOL indicate that while some 
symptoms, such as obstipation, vomiting or hemiparesis, are almost always evident 
before, and have a direct influence on the deterioration of QOL (causal indicators), 
other symptoms including pain, anxiety or depression probably have a bidirectional 
relationship with QOL (effect indicators) (95). It is also important to note that different 
symptoms or aspects of their conditions can have differing importance for primary 
headache patients. This is exemplified by studies of the determinants of patient 
satisfaction with migraine treatment, with fast and complete headache relief being 
described by most migraineurs as their main preference, and freedom from associated 
symptoms being important for a smaller number of patients (96). The difference in the 
frequency of accompanying symptoms within the study populations (97) may also 
influence the correlations between clinical data and QOL scores. Finally, it must be 
borne in mind that, theoretically, symptom scores and QOL instruments measure two 
fundamentally different constructs, and the correlations we found support this notion. 
 
While the CHQQ scores of migraineurs showed significant correlations with most 
clinical data, the scores of TTH patients were not significantly correlated with the 
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clinical characteristics, apart from moderate correlations of headache severity and the 
physical and social dimensions. This may be explained in part by the fact that this group 
consisted of a fewer number of patients, and was itself heterogeneous as regards the 
headache frequency of the individuals. On the other hand, areas conceptually related to 
QOL, such as the ability to study, had been found to be more severely affected by 
migraine than by TTH, even after correction for pain intensity (98). Moreover, in this 
study significant correlations between the TTH group’s clinical characteristics and SF-
36 domains were also very rare: previous studies about QOL in TTH had similar results. 
In a sample of 25 chronic TTH patients, only four (bodily pain, vitality, social 
functioning and mental health) of the eight SF-36 domains were significantly correlated 
with headache frequency, and only one (social functioning) with headache intensity 
(99). In a German study, the SF-36 physical composite score (PCS) of TTH sufferers 
was significantly correlated with days with disability and days with analgesic use, but 
not with headache days/hours, days with severe headache and headache score. In the 
same study the PCS of migraineurs was significantly correlated with all clinical 
variables. Interestingly, the mental health composite score was not correlated with the 
clinical characteristics in either of the diagnostic groups (100). These studies and our 
results seem to indicate that the perceived effect of TTH on QOL is largely independent 
of the clinical characteristics of headache. 
 
Convergent validity was assessed by calculating the correlations between CHQQ and 
the SF-36 generic QOL instrument. The total score of our instrument correlated 
significantly with all SF-36 dimensions in the whole sample and the diagnostic 
subgroups, with the exception of the total score in TTH that was not correlated with SF-
36’s social functioning domain. CHQQ’s three dimensions had significant correlations 
with the majority of SF-36’s domains. Most correlations were of moderate strength (0.3 
to 0.5) in the whole sample and migraine group, while there was a high number of 
strong (>0.5) correlations between CHQQ scores and SF-36 domains in the TTH group. 
Correlation coefficients were higher in the TTH group (0.374–0.778) than in the 
migraine group (0.179–0.487). The strength of correlations was again similar to those 
found in previous validation studies. In the MSQOL validation study convergent 
validity was measured by calculating the correlations of MSQOL with the SF-36 
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domains: mostly moderate correlations were found with the exception of a strong (0.53) 
correlation with the mental health domain (52). The validation study of the MSQ2.1 
reported low-to-modest correlations between MSQ dimensions and the two component 
scores of the SF-36 (79). The fact that most correlations were moderate may be 
explained by three factors. First, SF-36 gathers data about the 4 preceding weeks, while 
the CHQQ asked questions about the last 2 weeks. Second, there are important 
differences between the items in the two instruments. The CHQQ asks questions about 
sleep, intrafamiliar relations, sex life and leisure activities, while these are not included 
in the SF-36. Furthermore, it is important to stress that the CHQQ explicitly asks about 
the way headaches influence the various areas, so limitations caused by other conditions 
were probably not taken into account by the patients, whereas SF-36, as a generic QOL 
measure, gathers information about the effect of one’s health in general (including the 
headaches) on QOL. The same three factors may also explain the lack of significant 
correlation between SF-36’s social functioning domain and CHQQ’s total score in TTH 
patients.  
 
Confronting the diagnostic subgroups’ headache specific QOL (discriminative or known 
group validity) lent further support to the validity of the instrument. It is important to 
stress that, as we had expected, migraine patients had numerically lower scores (worse 
QOL) for all items, dimensions and the total score, and that the difference was 
significant in most (with the exception of seven items). It therefore seemed that the 
CHQQ was able to disclose the differential effect of headache types on QOL. In this 
regard it is worth noting that in the present study the SF-36 questionnaire found a 
significantly different QOL between migraine and TTH only in four of its eight 
dimensions, and in two of them TTH sufferers had worse QOL, which is not consistent 
with the widespread notion of migraine being a more severe condition. 
 
We started developing the CHQQ with the intention of producing an instrument that 
examines the QOL of headache patients in detail. It was expected that the underlying 
factor structure would be complex. The analysis of the item–dimension correlations 
confirmed the hypothesized structure of the instrument. With the exception of one item, 
all the items showed the highest correlation with their intended dimensions. 
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An obvious issue with our study was the method of patient selection. As patients 
presenting at a tertiary center were involved, patients suffering from more severe 
headaches may have been over-represented in the sample. In fact, patients with more 
severe limitations may be more motivated to seek medical help in a specialized 
headache center. An indirect proof of this possibility may be the fact that migraineurs 
outnumbered TTH sufferers in this study, in spite of TTH being much more prevalent in 
the general population. A further limitation of our study was that most of the patients 
had migraine. This was due to the fact that we had chosen to enroll all consecutive 
outpatients who fulfilled the diagnostic criteria of migraine or TTH. Although the TTH 
group was much smaller, the reliability and validity measurements in this subgroup also 
showed that the psychometric properties of the instrument were adequate. This was 
further underscored by the fact that the instrument showed significant differences 
between the migraine and TTH groups, with TTH patients having better QOL. In this 
respect it is also worth noting that there were significant differences in the clinical 
characteristics of headache in the two groups, with migraineurs reporting higher values 
of disease duration, length of attacks (average, minimum and maximum), and severity 
of the attacks. Intriguingly, those clinical characteristics that were higher in the TTH 
group (signifying bigger disease load), i.e. attack frequency and number of days with 
headache, were the ones that showed fewer correlations with CHQQ’s items, 
dimensions and total score. A more precise assessment of the instrument’s usability 
would require samples drawn from the general population. 
 
Comparing the new instrument with previously developed headache-specific measures 
could have added further evidence about the validity of the instrument and may have 
yielded important data about its usability. However, due to a lack of validated 
Hungarian translations of headache-specific QOL instruments, this approach was not 
possible (the validation study of the Hungarian version of the MSQOL was only 
published in 2011 (59), after the enrollment to the present study had been terminated). 
Although the HIT-6 has been validated in Hungarian (101), due to the small sample size 
(only 35 Hungarian migraineurs diagnosed by their primary care physician were 
studied) and to the fact that, in a strict sense, HIT-6 is not a QOL instrument, we 
decided not to use it. 
DOI:10.14753/SE.2016.1860
81 
 
 
Regardless of these limitations, this study has provided sufficient evidence that the 
CHQQ was a reliable and valid instrument to measure QOL in episodic migraine and 
TTH.  
 
 
6.2.2. Validation in medication overuse headache  
 
We evaluated the psychometric properties of the Comprehensive Headache-related 
QOL Questionnaire in patients suffering from medication overuse headache. The 
majority of patients (81%) were overusing simple or combined NSAIDs, while only 
15% were triptan-overusers. The infrequent overuse of triptans was due to financial 
issues (the local health system covers only 30% of its price). The reliability of the 
questionnaire was adequate. Criterion validity results of the instrument showed negative 
correlations between the clinical data and CHQQ scores. Convergent validity results 
showed that the dimensions of the questionnaire have positive and almost always 
significant correlations with the SF-36 domains. During the examination of 
discriminative validity, we compared the CHQQ values of MOH patients to those of 
chronic tension type headache patients with no medication overuse, who had a similar 
headache frequency. We decided not to use patients with chronic migraine as a control 
group, as there was a huge overlap (from 65.5% to 73%) between chronic migraine and 
medication overuse in previous studies (104, 105) and also, 75% of our patients’ 
headaches met the IHS criteria for chronic migraine. While this consideration would not 
be relevant during assessment of an individual’s QOL, using clearly distinctive clinical 
groups are necessary for the purposes of a validation study. On the other hand, further 
studies are necessary to assess the validity of CHQQ in chronic migraine.  
A further limitation of this study is the relatively small sample size, therefore our results 
should be considered as preliminary, and they should be verified on a larger sample, 
preferably drawn from the general population. Nonetheless, such a validation study is 
important to confirm that the CHQQ’s psychometric properties in MOH are adequate 
for further testing. 
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6.2.3 Examination of responsivity in medication overuse headache 
 
This pilot study was conducted to evaluate the feasibility of using the Comprehensive 
Headache-related QOL Questionnaire as an outcome measure in a prophylactic 
treatment trial of medication overuse headache. At baseline, patients were found to have 
low headache-related quality of life that was comparable to the QOL of EM patients. 
Acute medication withdrawal and prophylactic treatment resulted in the improvement of 
the headache characteristics and also the QOL of patients. The highly significant 
changes in QOL indicate that the Comprehensive Headache-related Quality of life 
Questionnaire may be useful in monitoring the QOL in MOH patients undergoing 
headache prophylaxis. 
 
In this study, the baseline QOL of MOH patients was not significantly different from 
the QOL of a large group of patients with EM. This is in contrast with previous studies 
where MOH patients had lower generic QOL values than EM (103). Our findings might 
be explained partly by the limited number of MOH patients (ie. it is not sure whether 
the sample was representative of Hungarian MOH patients). Another plausible 
explanation is that during the chronification of the headache, the severity of pain and the 
accompanying symptoms usually decrease; moreover patients with frequent migraines 
tend to use abortive treatments in the early phase of attacks when the pain and 
accompanying symptoms are usually mild (91) and therefore their direct effect on QOL 
may be less robust.  
 
We observed highly significant improvements of both the clinical data/external 
measures of headache and headache-specific QOL after the treatment. This is not a 
common finding. A PubMed search on 30
th
  January 2014 identified 53 papers using the 
keywords ‘medication overuse headache’ and ‘quality of life’. Only six of these used 
QOL instruments as clinical endpoints in determining the effect of withdrawal 
treatment; headache-specific instruments were used in just three studies. Of these three 
studies, one did not find any significant effect of the treatment on QOL (111). So, to our 
knowledge this is the 3
rd
 study where the clinical improvement was paralleled by 
significant improvements of headache-specific QOL. Condition-specific QOL 
instruments are developed to better reflect the effect of a certain condition and its 
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treatment on QOL. The present study, showing that the CHQQ reflected the expected 
changes in QOL as the external measures of headache improved, is a small but 
important step about exploring the feasibility of using CHQQ in clinical trials.   
 
We found mild to moderate, but nonsignificant correlations between measures of 
clinical improvement and QOL improvement. The chance of finding significant 
correlations in any given study depends heavily on the number of subjects. While 
significant correlations would certainly lend further support to the criterion validity of 
the CHQQ, it was very unlikely that they would be encountered in such a small sample.  
The present study provides further evidence for the discriminative validity of the 
CHQQ, as there were significant differences between the pre-, and post-treatment 
values (dimensions, total score and also the majority of items). As the number of 
patients was small, most of the correlations between the changes in CHQQ values and 
headache characteristics were not significant. Nevertheless, the fact that in most patients 
the improvement of headache-related QOL was paralleled by a similar improvement of 
clinical variables may provide further evidence for the criterion validity of the CHQQ.  
 
This study had a number of limitations, such as the small sample size, the lack of 
psychological profile of the patients, the short data collection period and lack of follow-
up information. Because of the small number of patients the study was not able to 
answer whether in-, or outpatient withdrawal is more feasible, or the various 
prophylactic drugs we used are equally effective. Due to the lack of a longer follow-up 
period this study was not suited to examine whether the promising results we obtained 
remain stable over time. On the other hand, the present study confirmed the CHQQ’s 
ability to discern the improvement of MOH patients’ quality of life after successful 
treatment and therefore may be useful as an endpoint in headache trials. This study also 
corroborated our previous hypothesis (113) about the possibility of successfully using 
CHQQ to measure QOL in headaches other than migraine or episodic tension type 
headache. Formal validation studies in MOH and other headaches are necessary to 
clarify this issue (114). 
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7. Conclusion  
 
Primary headaches constitute a public health problem, affecting 46% of the adult 
population globally, causing a significant amount of disability and poor health related 
quality of life. Health-related QOL reflects the patient’s perspective of the way medical 
conditions and their treatment influence their position in life. Measuring QOL can give 
a unique insight into the patient’s condition as the doctor’s evaluation of the effect of 
illness can be markedly different from the patient’s perspective. Along with other 
patient reported outcomes that measure disability, illness intrusiveness or other 
consequences of health problems, measuring QOL has become an important means of 
assessing the burden of disease and the efficacy of therapeutic interventions.  
 
The aim of our studies was to assess the impact of common headache types on HRQoL. 
Our first study investigated quality of life in cluster headache. After that, we set out to 
develop a new comprehensive headache-specific questionnaire, which would assess 
several aspects of QOL. We then examined the psychometrical properties of our new 
questionnaire, called Comprehensive Headache-related QOL Questionnaire, in several 
headache types.  
 
Our first study investigated the health-related and condition-specific quality of life in 
episodic cluster headache. Although there had been sporadic studies measuring generic 
QOL in CH, headache-related QOL had previously not been studied. In our study, 
generic and headache-specific HRQoL were found to be seriously impaired during the 
cluster period. This impairment was at least as severe as in migraineurs for most 
HRQoL domains; bodily pain and social functioning were significantly worse in CH. 
After the termination of the cluster period the HRQoL of patients was similar to that of 
headache-free controls. MSQ2.1 and SF-36 were not sensitive enough to the difference 
between the QOL profiles of CH patients and migraineurs, so it was concluded that 
these two instruments may not capture some essential aspects of CH. Among others, 
these observations also motivated us to develop a new headache specific HRQoL 
instrument. 
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In our next study, we developed a new headache-specific HRQoL questionnaire, called 
Comprehensive Headache-related Quality of life Questionnaire, which aims to assess 
the patients’ HRQoL in a more detailed fashion. The development of the questionnaire 
consisted of the following steps: relevant item identification, development of a draft 
version, psychometric testing of the draft version and development of the final version. 
The psychometric properties of the item scores, dimension scores and total score of the 
draft version were tested in a group of 117 migraineurs. After omitting 2 questions, we 
confirmed that the resulting 23-item questionnaire was adequate for further testing.  
 
We then validated the new questionnaire in three main headache types (migraine, 
tension-type headache and medication overuse headache). According to the 
internationally accepted recommendations, we investigated the reliability and validity 
(criterion, convergent and discriminative validity) of the questionnaire during the 
psychometric testing.  
 
We calculated the internal consistency to assess the reliability of the questionnaire. 
Cronbach’s alpha was adequate in all the diagnostic subgroups, and in several 
subgroups its value exceeded the very conservative level of 0.9, which represents an 
excellent reliability.  
 
When assessing the criterion validity of the questionnaire, the clinical data of patients 
showed negative correlations with the QOL scores, as expected. In all diagnostic 
subgroups QOL scores correlated mostly and strongest with pain intensity. This 
confirms the finding, which had been observed by other working groups, too, that pain 
intensity is the main determinant of QOL in headache. Surprisingly, QOL scores 
showed less correlations with headache and attack frequency. The strength of the 
correlations we observed (weak to moderate) was comparable to those found in other 
validation studies, and can be explained by the conception of QOL, which is based on 
the patients’ subjective interpretation, while the clinical data are considered more 
objective. In our studies, clinical data were gathered from the patients’ headache diaries. 
In the field of headache research, by a general consensus, the headache diary is 
considered to be objective. It is worth noting, that the SF-36 domains showed a smaller 
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number of weaker correlations with clinical data, and in the subgroup of MOH patients, 
we found significant positive correlations  between disease duration and 4 of the 8 SF-
36 domains (higher quality of life with longer disease duration), which is contrary to the 
clinical expectations. This suggests, that according to our original intentions, the CHQQ 
may be more sensitive to the clinical characteristics of headaches than the generic 
instrument SF-36. 
 
While assessing the convergent validity we examined the correlations of the different 
patient subgroups’ quality of life scores with the domains of the SF-36. Most 
correlations were of weak to moderate strength, which was similar to those found in 
previous validation studies and studies using validated questionnaires, including our 
own earlier study.  
The fact that most correlations were moderate may be explained by the fact that 
although the two questionnaires measure similar constructs, there are several differences 
on the level of items; moreover, the CHQQ investigates also such domains (e.g. sleep, 
leisure activities), which are not included in SF-36. 
 
While assessing the discriminative validity we found that the questionnaire was able to 
disclose the differential effect of different headache types on quality of life. Confronting 
the diagnostic subgroups’ headache specific quality of life (migraine versus tension type 
headache and medication overuse headache versus chronic tension type headache) 
significant differences were measured by our questionnaire. As expected, QOL was 
significant worse in migraineurs than in TTH patients and also in MOH patients than in 
chronic TTH patients. It is worth noting, that in our earlier studies, the difference of 
QOL scores between CH patients and migraineurs was significant only in 2 of the 8 SF-
36 domains, and similarly the difference between the SF-36 scores of migraineurs and 
TTH patients was only significant in 4 domains (in two of which migraineurs had better 
QOL, which was contrary to our expectations). It is also important, that limitations 
measured by MSQ caused by CH were not significantly different than than those of 
migraineurs. These findings suggest that the discriminative validity of CHQQ is 
adequate, and it may be able to detect differences between the impact of different 
headache types better than previously used questionnaires.   
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Further we observed that the responsivity of our questionnaire was adequate. In a pilot 
study the complex treatment of medication overuse headache patients resulted in a 
significant improvement of the headache characteristics and simultaneously in highly 
significant changes of quality of life. This is an important finding as only a few similar 
studies in MOH have been done as yet, and the applied methods have not measured 
QOL improvement in all cases. 
 
The length and ease of use of a questionnaire are important aspects of its usability. In 
our studies the questionnaire did not present any difficulty for the patients and we 
observed a high response rate, which indicated that the length of this questionnaire 
would probably not be a significant limiting aspect of its clinical use.  
 
In summary, the psychometric properties of the new questionnaire were adequate in all 
diagnostic subgroups. The reliability and validity of CHQQ were appropriate; the 
questionnaire was capable to specify and follow the impact of headache on QOL and it 
was useful in monitoring the effectiveness of headache therapy. To the best of our 
knowledge, CHQQ is the first among the quality of life questionnaires used in headache 
research to have been formally validated in the most important headache types, ie. 
migraine, TTH and MOH. The aim of our working group is encouraging the widespread 
use of the new questionnaire in clinical practice as well as in headache research. In our 
current studies the new questionnaire is being validated in other languages (English, 
Farsi and Serbian). Furthermore, we already have preliminary data for a validation study 
in cluster headache. Our studies were performed on patients from specialized headache 
centers, where patients with more serious headaches are probably overrepresented. 
Therefore, for a more accurate assessment of the questionnaire’s usefulness, we are 
preparing a study which will investigate a sample of the general population. We are also 
planning studies which would evaluate the effect of prophylactic and acute headache 
treatment on QOL.  
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The new results generated by our studies are the following: 
 
1. We investigated the quality of life in cluster headache in details. During the active period 
of CH, patients had significantly lower generic and headache-specific HRQoL than healthy 
controls. The impact of CH on HRQoL was comparable with that of migraineurs; some 
domains were more affected than in migraineurs. After the termination of the cluster period 
the HRQoL of patients was similar to that of headache-free controls. Our study was the 
first, which investigated condition specific HRQoL in CH. 
 
2. We developed a new headache-specific HRQoL questionnaire, called Comprehensive 
Headache-related Quality of life Questionnaire, which aims to assess the patients’ HRQoL 
in a more detailed fashion.  
 
3. We examined the psychometric properties of CHQQ in the two most common and 
important primary headache types, ie. migraine and tension-type headache. The reliability 
and validity of the questionnaire were adequate in these headache types. The questionnaire 
detected significant differences in the effect of migraine and TTH on HRQoL. This 
difference was in accordance with the clinical experience, as migraineurs had lower scores 
than TTH patients. 
 
4. We performed a validation study of the questionnaire in patients suffering from 
medication overuse headache. Again, the reliability and validity of the questionnaire were 
adequate in this headache type. 
 
5. In a pilot study, we studied the responsiveness of the questionnaire in a group of MOH 
patients. The complex treatment of these patients resulted in the improvement of the 
headache characteristics and simultaneously in highly significant improvement in the QOL 
as measured by the new questionnaire. 
 
6. Our results indicate that the questionnaire may be useful in assessing the QOL of patients 
suffering from different forms of primary and secondary headaches, and also in monitoring 
the effect of headache treatments on QOL. 
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8. Summary 
 
Measuring health-related quality of life (HRQoL) is one of the most commonly used 
patient-reported outcomes. We examined HRQoL in different headache disorders using 
generic and headache-specific questionnaires.   
First we investigated the quality of life (QOL) in cluster headache (CH) in details. 
During the active period of CH, patients had significantly lower generic and headache-
specific HRQoL than healthy controls. The impact of CH on HRQoL was comparable 
with that of migraineurs; some domains were more affected than in migraineurs. After 
the termination of the cluster period the HRQoL of patients was similar to that of 
headache-free controls. Our study was the first, which investigated condition specific 
HRQoL in CH. 
After that, we developed a new headache-specific HRQoL questionnaire, called 
Comprehensive Headache-related Quality of life Questionnaire (CHQQ), which aims to 
assess the patients’ HRQoL in a more detailed fashion.  
We examined the psychometric properties of CHQQ in the two most common and 
important primary headache types, ie. migraine and tension-type headache (TTH). The 
reliability and validity of the questionnaire were adequate in these headache types. The 
questionnaire detected significant differences in the effect of migraine and TTH on 
HRQoL. This difference was in accordance with the clinical experience, as migraineurs 
had lower scores than TTH patients. 
We then performed a validation study of the questionnaire in patients suffering from 
medication overuse headache (MOH). Again, the reliability and validity of the 
questionnaire were adequate in this headache type. 
In a pilot study, we studied the responsiveness of the questionnaire in a group of MOH 
patients. The complex treatment of these patients resulted in the improvement of the 
headache characteristics and simultaneously in highly significant improvement in the 
QOL as measured by the new questionnaire. 
Taken together, our results indicate that the questionnaire may be useful in assessing the 
QOL of patients suffering from different forms of primary and secondary headaches, 
and also in monitoring the effect of headache treatments on QOL. 
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Összefoglalás 
 
Az egészségfüggő életminőség (HRQoL) mérése az egyik leggyakrabban alkalmazott, a 
beteg beszámolóján alapuló mérés. Kutatásaink során a HRQoL-t vizsgáltuk különböző 
fejfájás betegségekben, általános és betegség-specifikus életminőség-kérdőívek 
felhasználásával.  
Elsőként cluster fejfájós (CF) betegek életminőségét vizsgáltuk részletesen. 
Vizsgálatunkkal megállapítottuk, hogy a CF aktív szakában, a cluster periódus alatt 
mind az általános, mind a fejfájás-specifikus életminőség szignifikánsan alacsonyabb, 
mint az egészséges kontrolloké. A CF életminőséget rontó hatása a migrénével 
összemérhető volt; egyes területekre a CF erősebb hatással volt, mint a migrén. A CF  
periódus megszűnte után az életminőség a fejfájásmentes kontrollokétól nem 
különbözött. A CF betegség-specifikus életminőségre gyakorolt hatását korábban nem 
vizsgálták. 
Ezt követően kifejlesztettünk egy új fejfájás-specifikus kérdőívet, a Fejfájással 
Kapcsolatos Átfogó Életminőség-Kérdőívet, melynek célja a betegek életminőségének  
a korábbiaknál részletesebb vizsgálata.  A Fejfájással Kapcsolatos Átfogó Életminőség-
Kérdőív pszichometriai tulajdonságait a két leggyakoribb és legjelentősebb fejfájás 
kórképben, migrénben és tenziós fejfájásban (TF) vizsgáltuk. A kérdőív 
megbízhatósága és érvényessége megfelelőnek bizonyult ezen kórképekben. A kérdőív 
a migrén és a TF életminőségre kifejtett hatása között szignifikáns különbséget mért. A 
klinikai tapasztalatnak megfelelően, a migrénesek életminősége rosszabb volt, mint a 
TF-ban szenvedőké. 
Következő vizsgálatunkban a kérdőív validálálását  gyógyszer-túlhasználathoz társuló 
fejfájás (GyTTF) miatt kezelt betegek körében végeztük el. Ebben a kórképben szintén 
megfelelő volt a kérdőív megbízhatósága és érvényessége. 
Egy próbavizsgálatban a kérdőív érzékenységét vizsgáltuk GyTTF miatt kezelt 
betegcsoportban. A fejfájás komplex kezelése javulást eredményezett a klinikai 
végpontokban, melyet a kérdőívvel mért életminőség szignifikáns javulása kísért. 
Összefoglalva, eredményeink alapján a kérdőív alkalmas az életminőség mérésére az 
elsődleges és másodlagos fejfájás betegségek különböző formáiban, valamint 
felhasználható a fejfájás kezelésének hatékonyságának követésére. 
DOI:10.14753/SE.2016.1860
91 
 
9. References 
 
1.        World Health Organization. (1946) WHO definition of Health. Official Records 
of the World Health Organization, 2:100. 
2. Schipper H. J. (1983) Why measure quality of life? Can Med Assoc, 128:1367–
1370. 
3. WHOQOL. (1993) Study protocol for the World Health Organization project to 
develop a Quality of Life assessment instrument. Group Qual Life Res, 2:153-
159. 
4. Ware JE. Jr. (1991) Conceptualizing and measuring generic health outcomes. 
Cancer, 67(3):774-779. 
5. Schrag A.(2006) Quality of life and depression in Parkinson’s disease. J Neurol 
Sci, 248:151-157. 
6. Solari A, Filippini G, Mendozzi L, Ghezzi A, Cifani S, Barbieri E, Baldini S, 
Salmaggi A, Mantia LL, Farinotti M, Caputo D, Mosconi P. (1999) Validation 
of Italian multiple sclerosis quality of life 54 questionnaire. J Neurol Neurosurg 
Psychiatry, 67:158-162. 
7. Lopez Revuelta K, Garcia Lopez FJ, de Alvaro Moreno F, Alonso J. (2004) 
Perceived mental health at the start of dialysis as a predictor of morbidity and 
mortality in patients with end-stage renal disease (CALVIDIA Study). Nephrol 
Dial Transplant, 19:2347-2353. 
8. Lis CG, Gupta D, Grutsch JF. (2006) Patient satisfaction with quality of life as a 
predictor of survival in pancreatic cancer. Int J Gastrointest Cancer, 37:35-44. 
9. Mathews WC, May S. (2007) EuroQol (EQ-5D) measure of quality of life 
predicts mortality, emergency department utilization, and hospital discharge 
rates in HIV-infected adults under care. Health Qual Life Outcomes, 5:5. 
10. Guyatt GH, Feeny DH, Patrick DL. (1993) Measuring health related quality of 
life. Ann Intern Med, 118:622-629. 
11. Ware Jr. JE. (2000) SF-36 Health Survey update. Spine, 25:3130-3139. 
12. Mathews WC, May S.(2007) EuroQol (EQ-5D) measure of quality of life 
predicts mortality, emergency department utilization, and hospital discharge 
rates in HIV-infected adults under care. Health Qual Life Outcomes, 25:5. 
DOI:10.14753/SE.2016.1860
92 
 
13. Szende A, Németh R. (2003) Health-related quality of life of the Hungarian 
population. Orv. Hetilap, 144:1667-1674. 
14. Lund E, Gram IT. (1988) Response rate according to title and length of 
questionnaire. Scand J Soc Med, 26:154-160. 
15. Jepson C, Asch DA, Hershey JC, Ubel PA. (2005) In a mailed physician survey, 
questionnaire length had a threshold effect on response rate. J Clin Epidemiol, 
58:103-105. 
16. Crocker LM, Algina J. Introduction to Classical and Modern Test Theory. Holt, 
Rinehart and Winston Publishing Company, New York. 1986 
17. McCauley C, Bremer BA. (1991) Subjective quality of life measures for 
evaluating medical intervention. Evaluation and The Health Professions, 14:371-
387. 
18. Anastasi A. Psychological Testing. MacMillan Publishing Company, New York. 
1990 
19. Bland JM, Altman GA. (1997) Statistics notes: Cronbach’s alpha. BMJ, 
314:572. 
20. Terwee CB
 
, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, 
Bouter LM, de Vet HC. (2007)  Quality criteria were proposed for measurement 
properties of health status questionnaires. J Clin Epidemiol, 60:34-42. 
21. Lohr KN
 
, Aaronson NK, Alonso J, Burnam MA, Patrick DL, Perrin EB, Roberts 
JS.  (1996)  Evaluating quality-of-life and health status instruments: 
development of scientific review criteria. Clin Ther, 18:979-992. 
22. Guillemin F, Bombardier C, Beaton D. (1993) Cross-cultural adaptation of  
health related quality of life measures: literature review and proposed  
guidelines. J Clin Epidemiol, 46:1417-1432. 
23. Headache Classification Subcommittee of the International Headache Society. 
(2004) The International Classification of Headache Disorders: 2nd edition. 
24(1):9-160. 
24. Tovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton RB,  Scher Al, Steiner TJ,  
Zwart J-A. (2007) The global burden of headache: a documentation of headache 
prevalence and disability worldwide. Cephalalgia, 27(3):193-210. 
25. Russell MB. (2004) Epidemiology and genetics of cluster headache. Lancet 
Neurology,  3(5):279-283. 
DOI:10.14753/SE.2016.1860
93 
 
26. Westergaard ML, Hansen EH, Glümer C, Olesen J, Jensen RH. (2014) 
Definitions of medication-overuse headache in population-based studies and 
their implications on prevalence estimates: A systematic review. Cephalalgia, 
34(6):409-425. 
27. Jensen R, Bendtsen L. (2008) Medication overuse headache in Scandinavia. 
Cephalalgia, 28:1237-1239. 
28. Olesen J, Gustavsson A, Svensson M, Wittchen H.-U, Jönsson B. (2012) The 
economic cost of brain disorders in Europe. European Journal of Neurology, 
19:155-162. 
29. Manhalter N, Palásti Á, Bozsik G, Áfra J, Ertsey C. (2010) Examining the 
psychometric properties of a new quality of life questionnaire in migraineurs 
Ideggyogy Sz, 63:305-313. 
30. Ertsey C. (2009) Az elsődleges fejfájások klasszifikációja, A migrén 
epidemiológiája, A fejfájásban szenvedő betegek kivizsgálási stratégiája, Az 
elsődleges fejfájások kezelési protokollja, A fejfájás centrumok kritériumai 2. 
Kiadás. Cephalalgia Hungarica, 9. 
31. Ertsey C. (2010) A fejfájás centrumok helyzete Magyarországon. Cephalalgia 
Hungarica, 20:7. 
32. Bussone G, Usai S, Grazzi L, Rigamonti A, Solari A, D'Amico D (2004) 
Disability and quality of life in different primary headaches: results from Italian 
studies. Neurol Sci, 25(3):105-107. 
33. Ertsey C
 
, Manhalter N, Bozsik G, Afra J, Jelencsik I. (2004) Health-related and 
condition-specific quality of life in episodic cluster headache. Cephalalgia, 
24:188-196. 
34. D'Amico D, Rigamonti A, Solari A, Leone M, Usai S, Grazzi L, Bussone G. 
(2002) Health-related quality of life in patients with cluster headache during 
active periods. Cephalalgia, 22:818-821. 
35. Holroyd KA, Stensland M, Lipchik GL, Hill KR, O'Donnell FS, Cordingley G. 
(2000) Psychosocial correlates and impact of chronic tension-type headaches. 
Headache, 40:3-16. 
36. Guitera V
 
, Muñoz P, Castillo J, Pascual J. Quality of life in chronic daily 
headache: a study in a general population. (2002) Neurology, 58:1062-1065. 
37. Osterhaus JT, Townsend RJ, Gandek B, Ware JE. (1994) Measuring the 
functional status and well-being of patients with migraine headache. Headache, 
34:337-343. 
DOI:10.14753/SE.2016.1860
94 
 
38. Solomon GD, Skobieranda FG, Gragg LA. (1933) Quality of life and well-being 
of headache patients: measurement by the medical outcomes study instrument. 
Headache,  33:351-358. 
39. Wells KB
 
, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, 
Greenfield S, Ware J. The functioning and well-being of depressed patients 
(1989) Results from the Medical Outcomes Study. JAMA, 262:914-919. 
40. Cole JC, Lin P, Rupnow MFT. Validation of the Migraine-Specific Quality of 
Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing 
prophylactic migraine treatment. Quality of Life Research, 16:1231-1237. 
41. Garcia-Monco JC
 
, Foncea N, Bilbao A, Ruiz de Velasco I, Gomez-Beldarrain 
M. (2007)  Impact of preventive therapy with nadolol and topiramate on the 
quality of life of migraine patients. Cephalalgia, 27:920-928. 
 
42. Dahlöf C , Loder E, Diamond M, Rupnow M, Papadopoulos G, Mao L. (2007) 
The impact of migraine prevention on daily activities: a longitudinal and 
responder analysis from three topiramate placebo-controlled clinical trials. 
Health Qual Life Outcomes, 4:5-56. 
43. Santanello NC
 
, Polis AB, Hartmaier SL, Kramer MS, Block GA, Silberstein 
SD. Improvement in migraine-specific quality of life in a clinical trial of 
rizatriptan. Cephalalgia, 17:867-872. 
44. Géraud G, Valette C. (2000) Sumatriptan nasal spray 20 mg: Efficacy, tolerance 
and quality of life in migraine patients.  Revue Neurologique, 156:646-653. 
45. Solomon GD, Skobieranda FG, Gragg LA. Does quality of life differ among 
headache diagnoses? Analysis using the medical outcomes study instrument. 
(1994) Headache, 34:143-147. 
46. Ware J E Jr, Sherbourne C D. The MOS 36-item short-form health survey (SF-
36). I. Conceptual framework and item selection. (1992) Medical Care, 
30(6):473-483. 
47. Stewart AL, Ware JE. Measuring functioning and wellbeing: the medical 
outcomes study approach. Duke University Press, Durham, NC. 1992:6 
48. Ware J Jr. (2003) SF-36 Health Survey update. [WWW document]. URL 
http://www.sf-36.org/tools/SF36bookchapter.shtml.  
49. Stewart AL, Hays RD, Ware JE Jr. (1988) The MOS short-form general health 
survey. Reliability and validity in a patient population.  Med Care, 26:724-735. 
DOI:10.14753/SE.2016.1860
95 
 
50. Ware JE, Kosinski M. Improvements in the content and scoring of the SF-36 
Health Survey Version 2. SF-36 Users  Site at http://www.SF-
36.com/news/SF36–20.html. 
51. Jhingran P, Osterhaus JT, Miller DW. Development and validation of the 
migraine-specific quality of life questionnaire. (1998) Headache, 38:295-302. 
52. Wagner TH
 
, Patrick DL, Galer BS, Berzon RA. (1996) . A new instrument to 
assess the long-term quality of life effects from migraine: Development and 
psychometric testing of the MSQOL. Headache, 36:484-492. 
53. Santanello NC, Hartmaier SL, Epstein RS, Silberstein SD. (1995)Validation of a 
new quality of life questionnaire for acute migraine headache. Headache, 
35:330-337. 
54. Richard A
 
, Henry P, Chazot G, Massiou H, Tison S, Marconnet R, Chicoye A, 
d'Allens H. (1993) Qualite´ de vie et migraine. Validation du questionnaire 
QVM en consultation hospitaliere et en medecine generale. Therapie, 48:89-96. 
55. Kosinski M, Bayliss MS, Bjorner JB W, Ware Jr JE, Garber WH, Batenhorst A, 
Cady R, Dahlöf CGH, Dowson A, Tepper S. (2003) A six-item short-form 
survey for measuring headache impact: The HIT-6™. Quality of Life Research, 
12:963-974. 
56. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner A, Liberman JN, 
Sawyer J. (1999) An international study to assess reliability of the Migraine 
Disability Assessment (MIDAS) score. Neurology, 53:988-994. 
57. Bagley CL
 
, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, Kosinski 
M. (2012). Validating Migraine-Specific Quality of life questionnaire v2.1 in 
episodic and chronic migraine. Headache, 52:409-421. 
58. Patrick DL, Hurst BC, Hughes J. Further development and testing of the 
Migraine-Specific Quality of Life (MSQOL) measure. (2000) Headache, 40:550-
560. 
59. Berghammer R, Zsombok T. Examination of the quality of life of migraineurs 
and tension headache patients in connection with impulsivity, empathy, 
depression, and vital exhaustion. (2011) Mentalhigiene es Pszichoszomatika, 
12:173-189. 
60. Pini LA, Cicero A F G, Sandrini M. (2001) Long-term followup of patients 
treated for chronic headache with analgesic overuse. Cephalalgia, 21:878-883. 
61.  Duru G, Auray JP, Gaudin AF, Dartigues JF, Henry P, Lantéri-Minet M, Lucas 
C, Pradalier A, Chazot G, El Hasnaoui A  (2004) Impact of headache on quality 
DOI:10.14753/SE.2016.1860
96 
 
of life in a general population survey in France (GRIM2000 Study). Headache, 
44:571-580. 
62. Simić S, Slankamenac P, Kopitović A, Jovin Z, Banić-Horvat S. (2008) Quality 
of life research in patients suffering from tension type headache. Med Pregl, 
61:215-221. 
63. Yang M, Rendas-Baum R, Varon SF, Kosinski M. (2011) Validation of the 
Headache Impact Test (HIT-6TM) across episodic and chronic migraine. 
Cephalalgia, 31:357-367. 
64. Coeytaux RR, Linville JC. (2007) Chronic daily headache in a primary care 
population: prevalence and Headache Impact Test scores. Headache, 47:7-12. 
65. Abbott RB, Hui KK, Hays RD, Li MD, Pan T. (2007) A randomized controlled 
trial of tai chi for tension headaches. Evid Based Complement Alternat Med, 
4:107-113. 
66. Gesztelyi G, Bereczki D. (2004) Primary headaches in an outpatient neurology 
headache clinic in East Hungary. Eur J Neurol, 11:389-395. 
67. Czimbalmos A; Nagy Z; Varga Z; Husztik P. (1999) Measuring patient 
satisfaction with the SF-36 questionnaire: determining the Hungarian normal 
values. Népegészségügy, 1:4-19. 
68. Dodick D W, Rozen T D, Goadsby P J, Silberstein S D. (2000) Cluster 
headache. Cephalalgia, 20:787-803. 
69. Anonymous. Introduction. [WWW document]. URL 
http://www.clusterheadaches.com/index.html2003. 
70. Santanello NC, Davies G, Allen C, Kramer M, Lipton R. (2002) Determinants of 
migraine-specific quality of life. Cephalalgia, 22:680-685. 
71. Bahra A, May A, Goadsby PJ. (2002) Cluster headache. A prospective clinical 
study with diagnostic implications. Neurology 58:354-561. 
72. Slevin ML
 
, Plant H, Lynch D, Drinkwater J, Gregory WM. (1988) Who should 
measure quality of life, the doctor or the patient? Br J Cancer, 57:109-112. 
73. Failde I, Ramos I J. Validity and reliability of the SF-36 Health Survey 
Questionnaire in patients with coronary artery disease. (2000) J Clin Epidemiol, 
55:359-365. 
74. Scheingraber S, Kurz T, Dralle H. (2002) Short- and long-term outcome and 
health-related quality of life after severe peritonitis. World J Surg, 26:667-671. 
DOI:10.14753/SE.2016.1860
97 
 
75. Soderman P, Malchau H. Validity and reliability of Swedish WOMAC 
osteoarthritis index: a self-administered disease-specific questionnaire 
(WOMAC) versus generic instruments (SF-36 and NHP). (2000) Acta Orthop 
Scand, 71:39-46. 
76. de Graaff JC, Ubbink DT, Kools EI, Chamuleau SA, Jacobs MJ. (2002) The 
impact of peripheral and coronary artery disease on health-related quality of life. 
Ann Vasc Surg, 16:495-500. 
77. Aaronson NK
 
, Acquadro C, Alonso J, Apolone G, Bucquet D, Bullinger M, 
Bungay K, Fukuhara S, Gandek B, Keller S. (1992) International Quality of Life 
Assessment (IQOLA) project. Qual Life Res, 1:349-351. 
78. Dahlöf C, Bouchard J, Cortelli P, Heywood J, Jansen JP, Pham S, Hirsch J, 
Adams J, Miller DW. (1997)  A multinational investigation of the impact of 
subcutaneous sumatriptan. II: Health-related quality of life. Pharmacoeconomics, 
1(11):24-34. 
79. Martin BC
 
, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, 
Jhingran P. (2000) Validity and reliability of the migraine-specific quality of life 
questionnaire (MSQ Version 2.1). Headache, 40:204-215. 
80. Adelman J, Sharfman J, Johnson R, Miller D, Clements B, Pait G, Gutterman D,  
Batenhorst A. (1996)  Impact of oral sumatriptan on workplace productivity, 
health-related quality of life, healthcare use and patient satisfaction with 
medication in nurses with migraine. Am J Managed Care, 2:1407-1416. 
81. Gross M L P, Dowson A J, Deavy L, Duthie T. (1996)  Impact of oral 
sumatriptan 50 mg on work productivity and quality of life in migraineurs. Br J 
Med Economics, 10:231-246. 
82. D’Alessandro R, Gamberini G, Benassi G, Morganti G, Cortelli P, Lugaresi E. 
(1986) Cluster headache in the Republic of San Marino. Cephalalgia, 6:159-162. 
83. Jürgens TP, Gaul C, Lindwurm A, Dresler T, Paelecke-Habermann Y, Schmidt-
Wilcke T, Lürding R, Henkel K, Leinisch E. (2011) Impairment in episodic and 
chronic cluster headache. Cephalalgia, 31(6):671-782. 
84. Jensen RM, Lyngberg A, Jensen R H. (2007) Burden of cluster headache. 
Cephalalgia, 27(6):535-541. 
85. Dahlhof C G. (1995) Health-related quality of life under six months’ treatment 
of migraine – an open clinic-based longitudinal study. Cephalalgia, 15:414-422. 
86. Bozsik Gy, Manhalter N, Ertsey C. (2005) Quality of life determinants in cluster 
headache and migraine. Cephalalgia, 22:654. 
DOI:10.14753/SE.2016.1860
98 
 
87. Manhalter N, Bozsik Gy, Ertsey C. (2006) Which quality of life domains are 
most affected by migraine. (2006) J Headache Pain. 7(1):30. 
88. C Ertsey, A Palasti, G Bozsik, J Afra, N Manhalter. (2007) Item response 
modeling in the development of a new headache-specific quality of life 
instrument. Cephalalgia, 27:1193. 
89. Jacobson GP
 
, Ramadan NM, Aggarwal SK, Newman CW. (1994) The Henry 
Ford Hospital Headache Disability Inventory (HDI). Neurology. 44:837-842. 
90. Holroyd KA
 
, Malinoski P, Davis MK, Lipchik GL. (1999) The three dimensions 
of headache impact: pain, disability and affective distress. Pain, 83:571-578. 
91. Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby 
PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, 
Steiner TJ; International Headache Society. (2005) The International 
Classification of Headache Disorders, 2nd Edition (ICHD-II) – revision of 
criteria for 8.2 Medication-overuse headache. Cephalalgia, 25:460-465. 
92. Burdine JN, Felix MR, Abel AL, Wiltraut CJ, Musselman YJ. (2000) The SF-12 
as a population health measure: an exploratory examination of potential for 
application. Health Serv Res, 35:885-904. 
93. Guyatt G H, Feeny D H, Patrick D L. (1993) Measuring health related quality of 
life. Ann Intern Med, 118:622-629.  
94. Osoba D. (2007) Translating the science of patient-reported outcomes 
assessment into clinical practice. J Natl Cancer Inst Monog, 37:5-11. 
95. Fayers PM, Hand DJ, Bjordal K, Groenvold M. (1997) Causal indicators in 
quality of life research. Qual Life Res, 6:393-406. 
96. Davies G M, Santanello N, Lipton R. (2000) Determinants of patient satisfaction 
with migraine therapy. Cephalalgia, 20:554-60.  
97. Silberstein S D. (1995) Migraine symptoms: results of a survey of self-reported 
migraineurs. Headache, 35:387-396. 
98. Bigal ME
 
, Bigal JM, Betti M, Bordini CA, Speciali JG. (2001) Evaluation of the 
impact of migraine and episodic tension-type headache on the quality of life and 
performance of a university student population. Headache, 41:710-719. 
99. Peñacoba-Puente C , Fernández-de-Las-Peñas C, González-Gutierrez JL, 
Miangolarra-Page JC, Pareja JA. (2008) Interaction between anxiety, depression, 
quality of life and clinical parameters in chronic tension-type headache. Eur J 
Pain, 12:886-894. 
DOI:10.14753/SE.2016.1860
99 
 
100. Hoppe A, Weidenhammer W, Wagenpfeil S, Melchart D, Linde K. (2009) 
Correlations of headache diary parameters, quality of life and disability scales. 
Headache, 49:868-878. 
101. Martin M
 
, Blaisdell B, Kwong JW, Bjorner JB. (2004) The Short-Form 
Headache Impact Test (HIT-6) was psychometrically equivalent in nine 
languages. J Clin Epidemiol, 57:1271-1278. 
102. Headache Classification Committee of the International Headache Society 
(1998) Classification and diagnostic criteria for headache disorders, cranial 
neuralgias and facial pain. Cephalalgia, 8(7):1-96. 
103. Lantéri-Minet M, Duru G, Mudge M, Cottrell S. (2011) Quality of 
lifeimpairment, disability and economic burden associated with chronic daily 
headache, focusing on chronic migraine with or without medication overuse: a 
systematic review. Cephalalgia, 31(7):837-850. 
104. Silberstein SD
 
, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, 
Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW. (2013) 
Onabotulinumtoxin A for treatment of chronicmigraine: PREEMPT 24-week 
pooled subgroup analysis of patients who had acute headache medication 
overuse at baseline. J Neurol Sci, 331(1-2):48-56. 
105. Mathew N T. (1993) Chronic refractory headache. Neurology, 43:26-33. 
106. Evers S, Jensen R. (2011) Treatment of medication overuse headache - guideline 
of the EFNS headache panel. Eur J Neurol, 18:1115-1121. 
107. Sandrini G
 
, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G. 
(2011) Botulinum toxin type-A in the prophylactic treatment ofmedication-
overuse headache: a multicenter, double-blind, randomized, placebo-controlled, 
parallel group study. J Headache Pain, 12(4):427-433. 
108. D’Amico D, Usai S, Grazzi L, Rigamonti A, Solari A, Leone M, Bussone G. 
(2003) Quality of life and disability in primary chronic daily headaches. Neurol 
Sci, 24(2):97-100. 
109. Zebenholzer K, Thamer M, Wöber C.(2012) Quality of life, depression,and 
anxiety 6 months after inpatient withdrawal in patients with medication overuse 
headache: an observational study. Clin J Pain, 28(4):284-290. 
110. Bøe MG, Salvesen R, Mygland A. (2009) Chronic daily headache with 
medication overuse: predictors of outcome 1 year after withdrawal therapy. Eur J 
Neurol, 16(6):705-712. 
DOI:10.14753/SE.2016.1860
100 
 
111. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, 
TOPMAT-MIG-201(TOP-CHROME) Study Group. (2007)Topiramate reduces 
headache days in chronic migraine: a randomized, double-blind, placebo-
controlled study. Cephalalgia, 27(7):814-823. 
112. Pini LA
 
, Guerzoni S, Cainazzo MM, Ferrari A, Sarchielli P, Tiraferri I, 
Ciccarese M, Zappaterra M. (2012) Nabilone for the treatment of medication 
overuse headache: results of a preliminary double-blind, active-controlled, 
randomized trial. J Headache Pain, 13(8):677-684. 
113. Manhalter N, Bozsik Gy, Palásti Á, Csépány É, Ertsey C. The validation of a 
new comprehensive headache-specific quality of life questionnaire. Cephalalgia, 
32(9):668-682. 
114. Gyüre T, Csépány É, Hajnal B, Kellermann I, Balogh E, Nagy Zs, Manhalter N, 
Bozsik Gy, Ertsey C. (2014) The Comprehensive Headache-related Quality of 
Life Questionnaire shows significant improvement after withdrawal treatment in 
medication overuse headache: a pilot study. Ideggyogy Sz, 67(5–6):169-176. 
 
 
  
DOI:10.14753/SE.2016.1860
101 
 
10. Publications 
 
Articles related to the thesis 
Gyüre T, Csépány É, Hajnal B, Kellermann I, Balogh E, Nagy Zs, Manhalter N, Bozsik 
Gy, Ertsey C. (2014) The Comprehensive Headache-related Quality of Life 
Questionnaire shows significant improvement after withdrawal treatment in medication 
overuse headache: a pilot study. Ideggyogy Sz, 67(5–6):169-176. 
 
Ertsey C, Palasti A, Bozsik G, Csepany E, Manhalter N. Perspectives for the 
Comprehensive Headache-Specific Quality of Life Questionnaire (CHQQ). (2013) A 
response to the Editorial 'Assessing the quality of health-related quality of life measures' 
by Lipton et al. Cephalalgia, 33(12):1063-1064.  
 
Manhalter N, Bozsik Gy, Palasti A, Csepany E, Ertsey C. (2012) The validation of a 
new comprehensive headache-specific quality of life questionnaire. Cephalalgia, 
32(9):668-682.  
 
Manhalter N, Palasti A, Bozsik Gy, Afra J, Ertsey C. (2010) Új életminőség-kérdőív 
pszichometriai tulajdonságainak vizsgálata migrénes betegek esetében. Ideggyógyászati 
szemle / Clinical neuroscience, 63(9-10):305-313.  
 
Ertsey C, Manhalter N, Bozsik Gy, Afra J, Jelencsik I. (2004) Health-related and 
condition-specific quality of life in episodic cluster headache. Cephalalgia, 24(3):188-
196.  
 
Other, relevant publications 
Ertsey C, Vesza Z, Bango M, Varga T, Nagyidei D, Manhalter N, Bozsik Gy (2012) 
A cluster fejfájás klinikumának prospektiv vizsgálata [Prospective study of the clinical 
features of cluster headache]. Ideggyógyászati szemle / Clinical neuroscience, 65(9-
10):307-314.  
 
Vesza Z, Varallyay G, Szoke K, Bozsik Gy, Manhalter N, Bereczki D, Ertsey C (2010) 
 Trigemino-autonomic headache related to Gasperini syndrome. Journal of Headache an 
Pain, 11(6):535-538.  
  
DOI:10.14753/SE.2016.1860
102 
 
11. Acknowledgments 
 
First of all  I am grateful to my thesis advisor, Dr. Csaba Ertsey, who  granted me the 
privilege to get involved in the activities of the Headache Workgroup  at the Department 
of Neurology of the Semmelweis University, in Budapest when  I was yet a medical 
student of the University.  
 
My work and the whole set of underlying publications have been completed under his 
supervision. Dr. Ertsey offered indispensable help to each phase of research, publishing 
results and the writing of this dissertation.  
 
I am particularly indebted to Dr. Magdolna Bokor, Head of Dept. of Neurology at Nyírő 
Gyula Hospital, in Budapest who gave her consent and persistent help for my post-
graduate studies, even amongst the daily realities of a general hospital. 
 
I wish to express my gratitude to Prof. Imre Szirmai for his decision to launch this 
research project and thanks to his successor, Prof. Dániel Bereczki, Head of the 
Department of Neurology of the Semmelweis University, in Budapest for the wide 
support he gave for carrying on with the commenced researches. 
 
 I owe with gratitude to Univ. Docent Josef  Spatt, Head of Neur. Rehab. Zentrum, in 
Wien, for his consent to sustain my commenced research works.  
 
Thanks  to my patients, who amongst the pains of headache tolerated the burdens of the 
examinations. 
 
And finally,  special thanks should go to my husband and daughter, for their patience 
and help. 
 
 
 
 
DOI:10.14753/SE.2016.1860
103 
 
12. Appendix  
 
12.1 Comprehensive Headache-related QOL Questionnaire 
This questionnaire was designed to investigate the impact of headaches. It can help us 
considerably in learning more about your headache and general health, and thus in the 
planning of further investigations and treatment. Your identity will not be revealed to third 
parties and the information you give us will only be used for research purposes. As you can 
see, this questionnaire consists of two separate parts. The first part starts at the bottom of this 
page with a question about the intensity of pain. The second part starts on the following page 
with five  possible responses to each question. The questions relate to the impact of 
headaches in many areas of life. It is important that you answer all questions.  
Thank you for taking part in this survey. 
Part 1 
In this part, we would like to learn how strong your headache is. Please indicate on the line 
below the intensity of your headache by placing a mark between “no pain” and “the worst 
pain a person could ever have ”. “The worst pain a person could ever have” is defined as the 
strongest possible pain, which you may not have necessarily experienced. For example, if you 
had renal colic before and it was worse than your headache, then the headache cannot be “the 
worst pain a person could ever have”. Also, do not mark “the worst pain a person could ever 
have ” if you had no other painful conditions apart from headaches, but you think that others 
may have experienced stronger pain than you have due to a headache or other conditions. 
If you have different types of headaches with different intensities, you can mark them with an 
explanatory note (e.g. migraine, milder headache).  
Intensity of the headache attack: 
  
      No pain                  The worst pain 
a person could ever 
have  
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Part 2     The following questions relate to the past four  weeks. In your answer, please make 
an “average” of the past 4 weeks. 
 
1. How much did your headache impair your ability to work? 
Not at all  Slightly  Moderately  Significantly Prevented 
me from working 
 
2. How much did your headache impair your ability to perform  household tasks (cleaning up, 
washing, cooking, gardening, minor repairs, etc.)?  
Not at all  Slightly  Moderately  Significantly Prevented 
me from working 
 
3. How much did your headache interfere with your social life  (e.g. going to the movie theater, 
theater, concert, pub, excursion, visiting friends, etc.)? 
Not at all  Slightly  Moderately  Very much Unable to do 
 
4. How much did your headache interfere with how you spend your leisure time (reading, 
listening to music, hobbies, etc.)?  
Not at all  Slightly  Moderately  Very much Unable to do 
 
5. How much did your headache interfere with the planning of longer leisure programs (such 
as weekend, outings )? (E.g., did you have to cancel or postpone something because of the 
headache?) 
Not at all  Slightly  Moderately  Very much Unable to do 
 
6. How much did your headache affect  your physical health (condition)? (E.g., in doing sports 
or heavy manual work?) 
Not at all  Slightly  Moderately  Significantly  Extremely  
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7. How much did your headache affect  your physical appearance (looks)? (Is your appearance 
worse because of the headache?) 
Not at all  Slightly  Moderately  Significantly Extremely 
 
8. How much did your headache interfere with the relationship to your family members 
(persons living in the same household as you)? 
Not at all  Slightly  Moderately  Very much Awfully 
 
9. How much did your headache interfere with your sex life? 
Not at all  Slightly  Moderately  Very much Awfully 
 
10. How much did your headache interfere with your sleep? 
Not at all  Slightly  Moderately  Very much Awfully 
 
11. How exhausted were you because of your headache? (How much was your energy reduced 
because of your headache?) 
Not at all  Slightly  Moderately  Very much Awfully 
 
12. How much did your headache influence your mood? (Were you depressed because of your 
heaache?)  
Not at all  Slightly  Moderately  Very much Awfully 
 
13. How much did your headache impair your memory? (Did you become more forgetful 
because of your headache?) 
Not at all  Slightly  Moderately  Very much Awfully 
 
DOI:10.14753/SE.2016.1860
106 
 
14. How much did your headache impair your concentration? (Did your headache make it 
difficult to concentrate on what your were doing?) 
Not at all  Slightly  Moderately  Very much Unable to do 
 
15. How much did your headache affect  your thinking?  
Not at all  Slightly  Moderately  Very much Unable to do 
 
16. In general, how much did your headache impair your health? 
Not at all  Slightly  Moderately  Very much Awfully 
 
17. Did you become irritable because of your headache? (Did you lose your temper more easily 
as compared to times when you have no headache?) 
Not at all  Slightly  Moderately  Very much Awfully 
 
18. Are you more anxious and/or nervous because of your headache? 
Not at all  Slightly  Moderately  Very much Awfully 
 
19. Do you use painkillers or other medications to stop your headache?  
Not at all  Very rarely  Sometimes Often  Very often 
 
20. How much does your headache affect  your financial situation? (Due to costs of medicine, 
loss of working hours, sick leave, etc.?) 
Not at all  Slightly  Moderately  Very much Extremely 
 
21. Do you feel ashamed of your headache or because of your headache? 
Not at all  Slightly  Moderately  Very much Extremely 
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22. How much do you worry because of your headache? 
Not at all  Slightly  Moderately  Very much Extremely 
 
23. How much does your headache interfere with your enjoyment of the good things in life or 
of life in general? 
Not at all  Slightly  Moderately  Very much Completely 
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12.2 Fejfájással Kapcsolatos Átfogó Életminőség-Kérdőív 
 
Tisztelt Betegünk! 
 
Ez a kérdőív a fejfájás hatásainak felmérésére szolgál. Nagy segítséget jelenthet ahhoz, hogy 
fejfájásáról és általános egészségi állapotáról még többet megtudjunk, és ezen keresztül segíti 
a további vizsgálatok és kezelés megtervezését. A kérdőív két önálló részből áll. Az első része 
itt a lap alján kezdődik, a fájdalom erősségére vonatkozó kérdéssel. Ha lapoz egyet, a 
következő oldalon kezdődik a második rész, ahol minden kérdésre öt lehetséges választ adhat. 
Ezek a kérdések a fejfájásnak az élet különböző  területeire gyakorolt hatásáról szólnak. Ennek 
a résznek a végén felteszünk pár kérdést azokról a gyógyszerekről, amelyeket pillanatnyilag a 
fejfájás kezelésére használ. Nagyon fontos, hogy minden kérdésre válaszoljon.  
Segítségét köszönjük. 
1. rész 
Itt azt szeretnénk megtudni, hogy fejfájása mennyire erős. Kérjük, a lenti vonalon jelölje be a 
fejfájás erősségét, a „nincs fájdalom” és a „maximális fájdalom” között. Maximális fájdalomnak 
az elképzelhető legerősebb fájdalmat tekintjük (nem biztos, hogy Ön átélt ilyet). Ha például 
volt már veseköves rohama, és az rosszabb volt bármelyik fejfájásánál, akkor a fejfájás nem 
lehet „maximális fájdalom”. Akkor se jelölje be a „maximális fájdalmat”, ha a fejfájáson kívül 
nem volt más fájdalmas betegsége, de úgy gondolja, hogy mások át szoktak élni az önénél 
erősebb fájdalmat fejfájás vagy más betegség miatt.  
Ha különböző típusú és erősségű fejfájásai is szoktak lenni, akkor ezeket különböző 
magyarázattal jelölheti meg (pl: migrénes fejfájás, enyhébb fejfájás). 
 
 
A fejfájás roham erőssége:   
      nincs fájdalom                                                                               maximális fájdalom 
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2. rész.     A következő kérdések az elmúlt négy hétre vonatkoznak. Kérjük, próbáljon 
a négy hét “átlaga” alapján válaszolni 
 
 
1. Mennyire zavarta a fejfájás a munkájának (munkahelyi tevékenységének) elvégzésében? 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
2. Mennyire zavarta a fejfájás a házimunka (takarítás, főzés, mosás, kerti munkák, kisebb 
javítások stb) elvégzésében? 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
3. Mennyire zavarta a fejfájás barátokkal stb. közös programjait (vendégség, mozi, színház, 
koncert, szórakozóhelyek, kirándulások stb.)? 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
4. Mennyire zavarta a fejfájás szabadidő eltöltésében (olvasás, zenehallgatás, hobbi stb)? 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
5. Mennyire akadályozta a fejfájás hosszabb programok (pl. hétvégék, utazások) tervezését? 
(Előfordult-e például olyan, hogy le kellett mondania vagy el kellett halasztania egy programot 
a fejfájás miatt?)  
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
6. Mennyire befolyásolta a fejfájás az ön fizikai egészségét (erőnlétét)? (Például a sportolás 
vagy nehéz fizikai munka kapcsán?) 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
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7. Mennyire befolyásolta a fejfájás az ön külsejét, megjelenését? (Azaz rosszabbul néz-e ki a 
fejfájás miatt?) 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
8. Mennyire zavarta a fejfájás a családtagokkal (azaz az önnel közös háztartásban élőkkel) való 
kapcsolatát? 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
9. Mennyire zavarta a fejfájás az ön szexuális életét? 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
10. Mennyire zavarta a fejfájás az alvásban? 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
11. Mennyire érezte magát kimerültnek a fejfájás miatt? (Mennyire csökkentette a fejfájás az 
ön energiáját?) 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
12. Mennyire befolyásolta a fejfájás az ön hangulatát? (Rosszabb lett-e a hangulata, kedve a 
fejfájás miatt?) 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
13. Mennyire befolyásolta a fejfájás az ön emlékezőtehetségét? (Feledékenyebb lett-e a 
fejfájás miatt?) 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
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14. Mennyire zavarta a fejfájás az összpontosításban? (Mennyire zavarta a fejfájás abban, hogy 
arra koncentráljon, amit éppen csinált?) 
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
15. Mennyire zavarta a fejfájás a gondolkodásban?   
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
16. Mennyire rontotta a fejfájás az ön egészségi állapotát általában véve?  
Egyáltalán nem Kicsit Közepesen Nagyon Lehetetlenné tette 
 
17. Ingerlékenyebbé vált a fejfájás miatt? (Könnyebben elveszti az önuralmát, ahhoz képest, 
amikor nem fáj a feje?) 
Egyáltalán nem Kicsit Közepesen Nagyon Borzasztóan 
 
18. Feszültebb, idegesebb a fejfájások miatt? 
Egyáltalán nem Kicsit Közepesen Nagyon Borzasztóan 
 
19. Használ-e fájdalomcsillapítót vagy más gyógyszert a fejfájás elmulasztására? 
Egyáltalán nem Kicsit Közepesen Gyakran Nagyon gyakran 
 
20. Mennyire befolyásolja a fejfájás az ön anyagi (pénzügyi) helyzetét? (A gyógyszerek árának, 
a kiesett munkaóráknak, betegszabadságnak, stb. köszönhetően) 
Egyáltalán nem Kicsit Közepesen Nagyon Borzasztóan 
 
21. Mennyire szégyenli a fejfájását, mennyire szégyenkezik a fejfájás miatt? 
Egyáltalán nem Kicsit Közepesen Nagyon Borzasztóan 
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22. Mennyire aggódik a fejfájás miatt? 
Egyáltalán nem Kicsit Közepesen Nagyon Borzasztóan 
 
23. Mennyire zavarja a fejfájás abban, hogy az élet jó dolgainak örüljön, az életet élvezze? 
Egyáltalán nem Kicsit Közepesen Nagyon  Borzasztóan 
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